[go: up one dir, main page]

WO2001098291A2 - 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders - Google Patents

1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders Download PDF

Info

Publication number
WO2001098291A2
WO2001098291A2 PCT/US2001/019720 US0119720W WO0198291A2 WO 2001098291 A2 WO2001098291 A2 WO 2001098291A2 US 0119720 W US0119720 W US 0119720W WO 0198291 A2 WO0198291 A2 WO 0198291A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
propen
phenyl
thien
vcam
Prior art date
Application number
PCT/US2001/019720
Other languages
English (en)
French (fr)
Other versions
WO2001098291A3 (en
Inventor
Charles Q. Meng
Liming Ni
James A. Sikorski
Lee K. Hoong
Original Assignee
Atherogenics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics, Inc. filed Critical Atherogenics, Inc.
Priority to IL15356501A priority Critical patent/IL153565A0/xx
Priority to EP01946583A priority patent/EP1330448A2/en
Priority to CA002413878A priority patent/CA2413878A1/en
Priority to BR0111889-7A priority patent/BR0111889A/pt
Priority to AU6861001A priority patent/AU6861001A/xx
Priority to JP2002504247A priority patent/JP2004501147A/ja
Priority to MXPA02012660A priority patent/MXPA02012660A/es
Priority to NZ523443A priority patent/NZ523443A/en
Publication of WO2001098291A2 publication Critical patent/WO2001098291A2/en
Publication of WO2001098291A3 publication Critical patent/WO2001098291A3/en
Priority to ZA2003/00134A priority patent/ZA200300134B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/794—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring
    • C07C49/796—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/86—Ketones containing a keto group bound to a six-membered aromatic ring containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Definitions

  • the present invention includes novel heteroaryl or heterocyclic l,3-bis-(substituted- phenyl)-2-propen-l-ones as well as methods and compositions for the treatment of disorders mediated by VCAM-l or MCP-1 and for the treatment of inflammatory disorders generally that include the administration of a l,3-bis-(substituted-phenyl)-2-propen-l-one that has at least one phenyl substituent that is an aryl, heteroaryl or heterocyclic moiety.
  • Adhesion of leukocytes to the endothelium represents a fundamental, early event in a wide variety of inflammatory conditions, autoimmune disorders and bacterial and viral infections.
  • Leukocyte recruitment to endothelium is mediated in part by the inducible expression of adhesion molecules on the surface of endothelial cells that interact with counterreceptors on immune cells.
  • Endothelial cells determine which types of leukocytes are recruited by selectively expressing specific adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-l), intercellular adhesion molecule-1 (ICAM-1), and E-selectin.
  • VCAM-l vascular cell adhesion molecule-1
  • ICAM-1 intercellular adhesion molecule-1
  • E-selectin E-selectin.
  • VCAM-l binds to the integrin VLA-4 expressed on lymphocytes, monocytes, macrophages, eosinophils, and basophils but not neutrophils. This interaction facilitates the firm adhesion of these leukocytes to the endothelium.
  • VCAM-1 is an inducible gene that is not expressed, or expressed at very low levels, in normal tissues.
  • VCAM-1 is upregulated in a number of inflammatory diseases, including arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.
  • inflammatory diseases including arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-re
  • Coronary heart disease primarily as a result of atherosclerosis, remains the leading cause of death in industrialized countries.
  • Atherosclerosis is a disease characterized by vascular inflammation, deposition of lipids in the arterial vessel wall and smooth muscle cell proliferation resulting in a narrowing of the vessel passages.
  • atherosclerotic lesions can become unstable resulting in plaque rupture, thrombosis, myocardial infarction and ischemic heart disease.
  • VCAM-1 expression has been shown to inhibit atherosclerosis in several animal models (Sundell et al., Circulation, 100: 42, 1999).
  • a monoclonal antibody against VCAM-1 has also been shown to inhibit neointimal formation in a mouse model of arterial wall injury (Oguchi, S., et al., Arterioscler. Thromb. Vase. Biol, 20: 1729-1736, 2000).
  • Asthma which is increasing in prevalence and morbidity world-wide, is a chronic inflammatory disease characterized by lung eosinophilia and bronchial hyperreactivity.
  • Eosinophils have been considered an important effector cell in the pathogenesis of asthma and other allergic diseases.
  • Activated eosinophils release proteins such as major basic protein (MBP) that have been demonstrated to induce bronchial hyperreactivity, one of the defining criteria of asthma (Bousquot, et al., N. Engl. J.
  • VCAM-1 is markedly upregulated on human bronchial vascular endothelium of subjects with asthma who have air flow limitation, when compared with subjects without asthma (Pilewski, et al., Am. J. Respir. Cell Mol. Biol, 12, 1-3,1995; Ohkawara, Y., et al., Am. J. Respir. Cell Mol. Biol, 12, 4-12, 1995; Gosset, P., et al., Int. Arch. Allergy Immunol. 106: 69-77, 1995; hacken, ⁇ . H., et al., Clin. Exp.
  • IL-12 knockout mice had fewer eosinophils and NCAM-1 expression than wildtype mice; however, administration of recombinant IL-12 at the time of ova sensitization and challenge restored lung NCAM-1 expression and eosinophilia (Wang, S., et al, J. Immunol, 166:2741-2749, 2001).
  • blocking the integrin receptors for NCAM-1 have had positive effects on animal models of asthma (Rabb et al., Am. J. Respir. Care Med.
  • NCAM-1 has been demonstrated to be upregulated 24 hrs after nasal allergen provocation in patients with seasonal allergic rhinitis but not in normal subjects (Braunstahl, G. J., et al, /. Allergy Clin. Immunol, 107: 469-476, 2001).
  • RA Rheumatoid arthritis
  • RA Rheumatoid arthritis
  • NCAM-1 expression on synovial fibroblasts is a clinical hallmark of RA (Li, P., et al., J. Immunol. 164:
  • NLA-4/NCAM-1 interactions may be the predominant mechanism for recruitment of leukocytes to the synovium (Dinther-Janssen, et al., J. Immunol. 147: 4207- 4210, 1991; Issekeutz and Issekeutz, Clin. Immunol. Immunopathol. 61:436-447, 1991;
  • VCAM-1 has been shown to be chemotactic for T cells (Kitani, A., et al., J. Immun. 161: 4931-8, 1998), and in addition to being a possible diagnostic marker for RA, may contribute to its pathogenesis by inducing migration and recruitment of T cells. VCAM-1 expressed on fibroblast-like synoviocytes has also been implicated in enhanced survival of activated synovial fluid B cells (Marinova, Mutafcheia, L., Arthritis Rheum. 43: 638-644, 2000) that may further contribute to RA pathogenesis.
  • VCAM-1 plays a role in SLE.
  • Expression of VCAM-1 is increased on dermal vessel endothelial cells in patients with active systematic lupus erythematosus (Jones, S. M., British J. Dermatol. 135: 678-686, 1996) and correlates with increased disease severity (Belmont et al., Arthritis Rheum. 37:376- 383, 1994).
  • VCAM-1 expression on mesangial cells in vitro can be stimulated by IL-1, TNF- ⁇ , and iNF ⁇ exposure as well as by anti-endothelial cell IgG fraction and anti-DNA autoantibodies from SLE patients (Wuthrich, Kidney Int. 42: 903-914, 1992; Papa, N. D., et al., Lupus, 8: 423-429, 1999; Lai, K. N., et al., Clin Immunol Immunopathol, 81: 229-238, 1996). Furthermore, soluble VCAM-1 is higher in SLE patients than in normal subjects (Mrowka, C, et al., Clin.
  • Acute transplant rejection occurs when the transplant recipient recognizes the grafted organ as "non-self "and mounts an immune response characterized by massive infiltration of immune cells, edema, and hemorrage that result in the death of the transplanted organ. Acute rejection occurs in a matter of hours or days and has been correlated with increased levels of VCAM-1 in tissues and in plasma (Tanio et al., Circulation, 89:1760-1768, 1994; Cosimi et al., J. Immunol. 144: 4604-4612, 1990; Pelletier, R, et al, Transplantation, 55: 315, 1992).
  • VCAM-1 A monoclonal antibody to VCAM-1 has been shown to inhibit cardiac allograft rejection in mice (Pelletier, R., J. Immunol, 149: 2473-2481, 1992; Pelletier, R., et al., Transplantation Proceedings, 25: 839-841, 1993; Orosz, C. G., et al., J. Heart and Lung Transplantation, 16: 889-904, 1997) and when given for 20 days can cause complete inhibition of rejection and long-term graft acceptance (Orosz C. G., et al., Transplantation, 56: 453-460, 1993).
  • Chronic graft rejection also known as allograft vasculopathy is distinct from acute transplant rejection and is a leading cause of late graft loss after renal and heart transplantation. Histologically it is characterized by concentric neointimal growth within vessels that is largely due to smooth muscle migration and proliferation. It is thought to be the result of endothelial damage brought about by several factors including: ischemia-reperfusion injury, immune complexes, hypertension, hyperlipidemia and viruses. All of these factors have been associated with induction of VCAM-1 in endothelial cells. There is also a strong correlation of soluble and tissue VCAM-1 levels with chronic rejection (Boratynska, M.,. Pol. Arch. Med.
  • Multiple sclerosis is a common demyelinating disorder of the central nervous system, causing patches of sclerosis (plaques) in the brain and spinal cord. It occurs in young adults and has protean clinical manifestations. It is well documented that VCAM-1 is expressed on brain microvascular endothelial cells in active lesions of multiple sclerosis (Lee S. J., et al., /. Neuroimmunol, 98: 77-88, 1998).
  • Experimental therapy of experimental autoimmune encephalomyelitis which is an animal model for multiple sclerosis, using antibodies against several adhesion molecules, including VCAM-1, clearly shows that adhesion molecules are critical for the pathogenesis of the disease (Benveniste et al., J. Neuroimmunol.
  • Diabetes mellitus is a metabolic disease in which carbohydrate utilization is reduced and that of lipid and protein is enhanced.
  • Evidence has accumulated that increased levels of adhesion molecules may play a functional pathophysiological role in diabetes (Wagner and Jil a, Hormone and Metabolic Research, 29: 627-630, 1997; Kado, S., Diabetes Res. Clin. Pract, 46: 143-8, 1999). It is caused by an absolute or relative deficiency of insulin and is characterized by chronic hyperglycemia, glycosuria, water and electrolyte loss, ketoacidosis, and coma.
  • Elevated circulating adhesion molecules including VCAM-1 have been detected in patients with diabetes and in experimental models of diabetes in animals (Lorini et al., Hormone Research, 48: 153, 1997; Otsuki et al, Diabetologia, 40: A440, 1997; Hart et al., FASEB J. 1LA340, 1997; Albertini et al., Diabetologia, 39: A240, 1996; Wagner et al., Diabetologia, 39: A205, 1996; Enghofer et al., Diabetologia, 39: A97, 1996; Koga M., Diabet. Med., 15: 661-667, 1998).
  • peripheral vasculopathies such as diabetic retinopathy and diabetic nephropathy. It is believed that adhesion of leukocytes to the peripheral vasculature plays a central role in the vasculopathies often associated with diabetes.
  • Crohn's disease also known as regional enteritis, is a subacute chronic inflammatory condition of unknown cause, involving the internal ileum and less frequently other parts of the gastrointestinal tract. It is characterized by patchy deep ulcers that may cause fistulas, and narrowing and thickening of the bowel by fibrosis and lymphocytic infiltration. Ulcerative colitis is a chronic disease of unknown cause characterized by ulceration of the colon and rectum, with rectal bleeding, mucosal crypt abscesses, inflammatory pseudopolyps, abdominal pain, and diarrhea.
  • VCAM-1 reflects the grade of intestinal inflammation in patients with Crohn's disease or ulcerative colitis (Jones, et al., Gut, 36: 724- 30, 1995; Goggins et al., Gastroenterology, 108: A825, 1995; Goeke and Manns, Gastroenterology, 106: A689, 1994; Goeke et al., /. Gasterokenterol. 32:480-486, 1997; Loftus et al., Gastroenterology, 108: A684, 1995; Tahami et al., Gastroenterology, 118: A344, 2000). Antibodies to VCAM-1 have been shown to ameliorate experimentally-induced colitis in mice (Soriano, A., Lab. Invest. 80: 1541-1551, 2000).
  • Psoriasis is a chronic skin disease characterized by erythematous scaling plaques as a result of keratinocyte hyperplasia, influx of immune cells and endothelial activation (Nickoloff, B. J., et al., J. Invest. Dermatol, 127: 871-884, 1991).
  • VCAM-1 is upregulated in psoriatic skin as compared to normal skin (Groves, R. W., J. Am. Acad. Dermatol, 29: 67-72, 1993; Uyemura, K., et al., J. Invest. Dermatol. 101: 701-705, 1993) and levels of circulating VCAM- 1 correlate with disease activity (Schopf, R. E., Br. J. Dermatol, 128: 34-7, 1993).
  • linoleic acid linolenic acid, arachidonic acid, linoleyl hydroperoxide (13-HPODE) and arachidonic hydroperoxide (15-HPETE) induce cell-surface gene expression of VCAM-1 but not ICAM-1 or E-selectin.
  • Saturated fatty acids such as stearic acid
  • monounsaturated fatty acids such as oleic acid
  • PCT WO 98/51662 filed by AtheroGenics, Inc. and listing as inventors Russell M. Medford, Patricia K. Somers, Lee K. Hoong, and Charles Q. Meng, claims priority to provisional application U.S.S.N. 60/047,020, filed on May 14, 1997.
  • This application discloses the use of a broad group of compounds as cardiovascular protectants that exhibit at least one, and sometimes a composite profile, of reducing cholesterol, lowering LDL, and inhibiting the expression of VCAM-1.
  • U.S. Patent No. 5,155,250 to Parker, et al. discloses that 2,6-dialkyl-4-silylphenols are antiatherosclerotic agents. The same compounds are disclosed as serum cholesterol lowering agents in PCT Publication No. WO 95/15760, published on June 15, 1995.
  • U.S. Patent No. 5,608,095 to Parker, et al. discloses that alkylated-4-silyl-phenols inhibit the peroxidation of LDL, lower plasma cholesterol, and inhibit the expression of VCAM-1, and thus are useful in the treatment of atherosclerosis.
  • PCT WO 98/51289 which claims priority to provisional application U.S.S.N. 60/047,020, filed on May 14, 1997 by Emory University listing Patty Somers as sole inventor, discloses the use of a group of compounds as cardiovascular protectants and antiinflammatory agents which exhibit at least one, and sometimes a composite profile, of reducing cholesterol, lowering LDL, and inhibiting the expression of VCAM-1 and thus can be used as antiinflammatory and cardivascular treat agents.
  • PCT WO 98/23581 discloses the use of benzamidoaldehydes and their use as cysteine protease inhibitors.
  • PCT WO 97/12613 of Cornicelli et al. discloses compounds for the inhibition of 15- lipogenase to treat and prevent inflammation or atherosclerosis.
  • Compounds disclosed include benzopyranoindole, benzimidazole, catacholes, benzoxadiazines, benzo[a]phenothiazine, or related compounds thereof.
  • Japanese Patent No. 06092950 to Masahiko et al. discloses preparation of epoxy compounds wherein electron deficient olefins such as acylstyrene derivatives, styrene derivatives, and cyclohexenone derivatives are efficiently oxidized by a hydrogen peroxide derivative in the presence of a primary or secondary amine in an organic solvent to give said epoxides which are useful intermediates for pharmaceutical and flavoring materials.
  • PCT WO 99/00114 discloses the use of certain chalcones, 1,3-bis-aromatic- ⁇ ropan-l-ones (dihydrochalcones), and l,3-bisaromatic-prop-2-yn-l-ones for the preparation of pharmaceutical compositions for the treatment of prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infections by viruses, iv) neoplastic disorders, and v) conditions cause by microorganisms or parasites.
  • PCT 96/20936 discloses thiazolidin-4-one derivatives of the formula:
  • the compounds which act as PAF antagonists or 5-lipoxygenase inhibitors.
  • the compounds are used in the prevention and treatment of inflammatory and allergic disorders mediated by platelet-activating factor and /or leukotrienes.
  • U.S. Patent No. 4,085,135 discloses 2'-(carboxymethoxy)-chalcones with antigastric and antiduodenal ulcer activities.
  • U.S. Patent No. 5,744,614 to Merkle et al. discloses a process for preparing 3,5- diarylpyrazoles and various derivatives thereof by reacting hydrazine hydrate with 1,3- diarylpropenone in the presence of sulfuric acid and an iodine compound.
  • U.S. Patent No. 5,951,541 to Wehlage et al. discloses the use of salts of aromatic hydroxy compounds, such as (hydroxyaryl)alkenone salts, as brighteners in aqueous acidic electroplating baths.
  • the invention discloses that such compounds have a lower vapor pressure than the known brighteners, as a single substance and in the electroplating baths,in order to avoid losses of substance. They also have high water solubility properties.
  • Japanese Patent No. 07330814 to Shigeki et al. discloses benzylacetophenone compounds as photoinitiator compounds.
  • Japanese Patent No. 04217621 to Tomomi discloses siloxane chalcone derivatives in sunscreens.
  • U.S. Patent No. 4,085,135 to Kyogoku et al. discloses a process for preparation of 2'- (carboxymethoxy)-chalcones having antigastric and anti duodenal activities with low toxicity and high absorptive ratio in the body. This patent suggests that the high absorptive ratio in the body is due to the 2'-carboxymethoxy group attached to the chalcone derivative.
  • US Patent No. 4,855,438 discloses the process for preparation of optically active 2- hydroxyethylazole derivatives which have fungicidal and plant growth-regulating action by reacting an ⁇ - ⁇ -unsaturated ketone which could include a chalcone or a chalcone derivative with an enantiomerically pure oxathiolane in the presence of a strongly basic organometallic compound and at temperatures ranging from -80 to 120 °C.
  • JP 63010720 to Nippon Kayaku Co., LTD discloses that chalcone derivatives of the following formula (wherein R 1 and R 2 are hydrogen or alkyl, and m and n are 0-3) are 5- lipoxygenase inhibitors and can be used in treating allergies.
  • JP 06116206 to Morinaga Milk industry Co. Ltd, Japan discloses chalcones of the following structure as 5-lipoxygenase inhibitors, wherein R is acyl and R ! -R 5 are hydrogen, lower alkyl, lower alkoxy or halo, and specifically that in which R is acyl and R ⁇ R 5 are hydrogen.
  • VCAM-1 is a mediator of chronic inflammatory disorders
  • a more general goal is to identify selective compounds and methods for suppressing the expression of redox sensitive genes or activating redox sensitive genes that are suppressed.
  • COPD chronic obstructive pulmonary disease
  • VCAM-1 examples include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.
  • arthritis asthma
  • dermatitis cystic fibrosis
  • cystic fibrosis post transplantation late and chronic solid organ rejection
  • multiple sclerosis systemic lupus erythematosis
  • inflammatory bowel diseases autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive
  • the compounds disclosed herein can also be used in the treatment of inflammatory skin diseases that are mediated by VCAM-1, as well as human endothelial disorders that are mediated by VCAM-1, which include, but are not limited to psoriasis, dermatitis, including eczematous dermatitis, Kaposi's sarcoma, multiple sclerosis, as well as proliferative disorders of smooth muscle cells .
  • the compounds disclosed herein can be selected to treat anti-inflammatory conditions that are mediated by mononuclear leucocytes.
  • the compounds of the present invention are selected for the prevention or treatment of tissue or organ transplant rejection.
  • Treatment and prevention of organ or tissue transplant rejection includes, but is not limited to treatment of recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, spleen, small bowel, or corneal transplants.
  • the compounds can also be used in the prevention or treatment of graft- versus- host disease, such as sometimes occurs following bone marrow transplantation.
  • the compounds described herein are useful in both the primary and adjunctive medical treatment of cardiovascular disease.
  • the compounds are used in primary treatment of, for example, coronary disease states including atherosclerosis, post- angioplasty restenosis, coronary artery diseases and angina.
  • the compounds can be administered to treat small vessel disease that is not treatable by surgery or angioplasty, or other vessel disease in which surgery is not an option.
  • the compounds can also be used to stabilize patients prior to revascularization therapy.
  • the l,3-bis-(substituted-phenyl)-2- propen-1-ones have the additional properties of inhibiting monocyte chemoattractant protein- 1 (MCP-1) and smooth muscle proliferation.
  • MCP-1 is a chemoattractant protein produced by endothelial cells, smooth muscle cells as well as macrophages. MCP-1 promotes integrin activation on endothelial cells thereby facilitating adhesion of leukocytes to VCAM-1, and MCP-1 is a chemoattractant for monocytes.
  • MCP-1 has been shown to play a role in leukocyte recruitment in a number of chronic inflammatory diseases including atherosclerosis, rheumatoid arthritis, and asthma. Its expression is upregulated in these diseases and as such inhibition of MCP-1 expression represents a desirable property of anti-inflammatory therapeutics. Furthermore, smooth muscle cell hyperplasia and resulting tissue remodeling and decreased organ function is yet another characteristic of many chronic inflammatory diseases including atherosclerosis, chronic transplant rejection and asthma. Inhibition of the hyperproliferation of smooth muscle cells is another desirable property for therapeutic compounds.
  • the invention provides a compound of the formula (I)
  • R 22 and R 23 are independently hydrogen or (C ⁇ -C )alkyl
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ are independently
  • R 1 is H, lower alkyl, an optionally substituted carbocycle, aryl, heteroaryl, heterocycle, alkylaryl, alkylheteroaryl, alkylheteroaryl or alkylheterocycle;
  • R 2 is an optionally substituted alkyl, alkenyl, alkynyl, aryl, carbocycle, heteroaryl, heterocycle, alkylaryl, alkylheteroaryl, alkylheteroaryl or alkylheterocycle;
  • R 22 and R 6 ⁇ or R 23 and R 6 ⁇ can join together to form a bridged carbocycle, aryl, heterocycle or heteroaromatic;
  • R 2 ⁇ and R 3 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ , R 5 ⁇ and R 6 ⁇ , R 2 ⁇ and R 3 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ or R 5 and R 6 ⁇ can independently join to form a bridged compound selected from the group consisting of an optionally substituted carbocycle, an optionally substituted cycloalkenyl, an optionally substituted cycloalkylcarbonyl, an optionally substituted cycloalkenylcarbonyl; an optionally substituted aryl, an optionally substituted heterocylic or an optionally substituted heteroaromatic, or alkylenedioxy or wherein the ring can include a carbonyl, cyclic ester, amide, amine, sulfonate, or phosphonate; ix) at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R
  • R x at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , or R 6 ⁇ , and at least one of R 2 ⁇ , R 3 ⁇ , R ⁇ , R 5 ⁇ or R 6 ⁇ is a substituent other than hydrogen.
  • the compound is of the formula (II):
  • R is independently H or lower alkyl, R is an optionally substituted alkyl; and at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , or R 6 ⁇ , and at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ or R 6 ⁇ is a substituent other than hydrogen.
  • R 4 ⁇ or R 5 ⁇ is optionally substituted heteroaryl or heterocycle; and at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , or R 6 is a substituent other than hydrogen.
  • R 4 ⁇ or R 5 ⁇ is optionally substituted heteroaryl or heterocycle; and at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , or R 6 ⁇ is a substituent other than hydrogen.
  • R 5 ⁇ is optionally substituted thienyl or benzothienyl; R 2 ⁇ ,
  • R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , or R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , and R 6 ⁇ are independently hydrogen, ethoxy, ethoxy, propoxy, benzyloxy, 4-carboxybenzyloxy, 4-ethoxycarbonylbenzyloxy, 4-aminobenzyloxy, fluoro, chloro, bromo, iodo, hydroxy, OCH 2 CO 2 H, SCH 2 CO 2 H, NHCH 2 CO 2 H, CO 2 H, pyrid-2- ylmethoxy, pyrid-3-ylmethoxy, pyrid-4-ylmethoxy; thien-2-ylmethoxy, thien-3-ylmethoxy, fur- 2-ylmethoxy, fur-3-ylmethoxy and at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , or R 6 is a substituent other than hydrogen.
  • R 6 ⁇ is or R 2 ⁇ and R 3 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ , R 5 ⁇ and R 6 ⁇ , R 2 ⁇ and R 3 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ or R 5 ⁇ and R 6 ⁇ join to form a carbocycle, aryl, heterocycle or heteroaromatic in which the carbocycle, aryl, heteroaryl or heterocycle is a 5, 6 or 7 membered ring, optionally conjugated to another carbocycle, aryl, heteroaryl or heterocycle.
  • the heteroaryl group is not an oxazole.
  • R 3 ⁇ and R 4 ⁇ or R 5 ⁇ and R 4 ⁇ join to form a 5- membered methylendioxyphenyl group.
  • one of the A or B rings has only hydrogen substituents.
  • the phenyl groups of the chalcone can be metabolized by ring hydroxylation (by oxidizing enzymes, including but not limited to cytochrome P450) or via break down of the chalcone double bond.
  • the present chalcones include a heteroaryl, aryl or heterocyclic group attached to one of the phenyl rings to increase the half life and thus bioavailability of the compound.
  • the addition of the heteroaryl, aryl or heterocyclic group can decrease the water solubility of the compound, which has the effect of actually limiting the bioavailability of the compound.
  • the chalcone contains both a heterocycle, heteroaromatic or aryl group on at least one of the A and B phenyl rings to limit the metabolism of the compound, and at least one group that increases the water solubility of the compound. Since phenyl hydroxylation typically occurs at the para position, in a preferred embodiment, the aryl, heteroaryl or heterocyclic group is positioned at the para position, or at a meta position that blocks para-hydroxylation. Alternatively, halogen, especially fluorine, increases metabolic stability when placed in the position(s) most susceptible to hydroxylation.
  • Bulky alkoxy groups like cyclopropyl methoxy, heteroarylalkoxy (for example, thienyl methoxy, furryl methoxy and pyridyl methoxy) and heterocyclealkoxy also increase metabolic stability when placed at the meta or para position. It has been observed that adding the group that increases water solubility to the B ring typically increases the water solubility more than when the same group is added to the A ring, however, this trend may not hold true in all cases.
  • Preferred water solubilizing groups are alkoxy, such as methoxy, OC(R 1 ) 2 CO H, SC(R 1 ) 2 CO 2 H, NHC(R 1 ) 2 CO 2 H or OC(R 1 ) 2 CO 2 H, wherein R 1 is H or lower alkyl.
  • any group that increases the water solubility of the compound can be used as substituents for R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ , specifically including but not limited to
  • Figure 1 is an illustration of non-limiting examples of compounds of the present invention.
  • Figure 2 is a bar chart graph of the inhibition of eosinophil recruitment (percent eosinophils in the peritoneal fluid) by 50 mg/kg/dose of 3-[5-(benzo[b]thien-2-yl)-2,4- dimethoxyphenyl]-l-(3,4,5-trimethoxyphenyl)-2-propen-l-one.
  • Test compound was administered by subcutaneously injection -24, -2, +2 and +6 hrs around the time of ovalbumin challenge. This is a model of allergic inflammation as eosinophils are the major leukocyte recruited into the peritoneum.
  • Figure 3 is a bar chart graph of the inhibition of paw edema in a mouse model of delayed type hypersensitivity by 50 mg/kg/dose of 3-[5-(benzo[b]thien-2-yl)-2,4- dimethoxyphenyl]-l-(3,4,5-trimethoxyphenyl)-2-propen-l-one.
  • the test compound was administered by intraperitoneal injection -24, -2 and +6 hrs around the time of metBSA challenge.
  • compounds of formula (I) inhibit the expression of VCAM- 1, and thus can be used to treat a patient with a disorder mediated by VCAM-1.
  • These compounds can be administered to a host as monotherapy, or if desired, in combination with another compound of formula (I) or another bioloigically active agent, as described in more detail below.
  • the compounds can be used to treat inflammatory disorders that are mediated by VCAM-1 including, but not limited to arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.
  • inflammatory disorders that are mediated by VCAM-1 including, but not limited to arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases,
  • the compounds disclosed herein can be used in the treatment of inflammatory skin diseases that are mediated by VCAM-1, and in particular, human endothelial disorders that are mediated by VCAM-1, which include, but are not limited to, psoriasis, dermatitis, including eczematous dermatitis, and Kaposi's sarcoma, as well as proliferative disorders of smooth muscle cells.
  • the compounds disclosed herein can be selected to treat anti-inflammatory conditions that are mediated by mononuclear leucocytes.
  • the compounds of the present invention can be selected for the prevention or treatment of tissue or organ transplant rejection.
  • Treatment and prevention of organ or tissue transplant rejection includes, but are not limited to treatment of recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, spleen, small bowel, or corneal transplants. They are also indicated for the prevention or treatment of graft-versus-host disease, which sometimes occurs following bone marrow transplantation.
  • the compounds described herein are useful in both the primary and adjunctive medical treatment of cardiovascular disease.
  • the compounds are used in primary treatment of, for example, coronary disease states including atherosclerosis, post- angioplasty restenosis, coronary artery diseases and angina.
  • the compounds can be administered to treat small vessel disease that is riot treatable by surgery or angioplasty, or other vessel disease in which surgery is not an option.
  • the compounds can also be used to stabilize patients prior to revascularization therapy.
  • compositions for the treatment of diseases or disorders mediated by VCAM-1 wherein such compositions comprise a VCAM- 1 inhibiting amount of a chalcone derivatives of the formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • the invention provides a method for treating a disease or disorder mediated by VCAM-1 comprising administering to a patient a VCAM-1 inhibiting effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides a method for treating cardiovascular and inflammatory disorders in a patient in need thereof comprising administering to said patient an VCAM-1 inhibiting effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides a method and composition for treating asthma or arthritis in a patient in need thereof comprising administering to said patient an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides compounds of formula (I) and their pharmaceutically acceptable salts or prodrugs:
  • the wavy line indicates that the compound can be in the form of the E or Z isomer
  • R 22 and R 23 are independently hydrogen or (C ⁇ -C )alkyl
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ are independently
  • polyoxyalkylene polyol alkyl, oxyalkylamino, alkylcarbonylalkyl, lower alkyl S(O)-lower alkyl, lower alkyl-S(O) 2 -lower alkyl; hydroxyalkyl, aralkoxy, heteroaryl lower alkoxy, heterocyclo lower alkoxy, heteroaryloxy, heterocycleoxy, aralkyl lower thioalkyl, heteroaralkyl lower thioalkyl, heterocycloalkyl lower thioalkyl, heteroaryl lower alkyl, heterocyclo lower alkyl, heteroarylthio lower alkyl, arylthio lower alkyl, heterocyclothio lower alkyl, heteroarylamino lower alkyl, heterocycloamino lower alkyl, arylsulfinyl lower alkyl, arylsulfonyl lower alkyl, any of which can be optionally substituted with a moiety that does not
  • R 1 is H, lower alkyl, an optionally substituted carbocycle, aryl, heteroaryl, heterocycle, alkylaryl, alkylheteroaryl, alkylheteroaryl or alkylheterocycle;
  • R 2 is an optionally substituted alkyl, alkenyl, alkynyl, aryl, carbocycle, heteroaryl, heterocycle, alkylaryl, alkylheteroaryl, alkylheteroaryl or alkylheterocycle;
  • R 22 and R 6 ⁇ or R 23 and R 6 ⁇ can join together to form a bridged carbocycle, aryl, heterocycle or heteroaromatic;
  • R 2 ⁇ and R 3 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ , R 5 ⁇ and R 6 ⁇ , R 2 ⁇ and R 3 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ or R 5 ⁇ and R 6 ⁇ can independently join to form a bridged compound selected from the group consisting of an optionally substituted carbocycle, an optionally substituted cycloalkenyl, an optionally substituted cycloalkylcarbonyl, an optionally substituted cycloaikenylcarbonyl; an optionally substituted aryl, an optionally substituted heterocylic or an optionally substituted heteroaromatic, or alkylenedioxy or wherein the ring can include a carbonyl, cyclic ester, amide, amine, sulfonate, or phosphonate;
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ or R 6 ⁇ is, or R 2 ⁇ and R 3 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ , R 5 ⁇ and R 6 ⁇ , R 2 ⁇ and R 3 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ or R 5 ⁇ and R 6 ⁇ come together to be, an aryl, heterocycle or heteroaromatic; and
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , or R 6 ⁇ at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , or R 6 ⁇ is a substituent other than hydrogen.
  • the compound is of the formula (II):
  • R is independently H or lower alkyl, R is an optionally substituted alkyl; and at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , or R 6 ⁇ , and at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ or R 6 ⁇ is a substituent other than hydrogen.
  • R 4 ⁇ or R 5 ⁇ is optionally substituted heteroaryl or heterocycle; and at least one of R 2 , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , or R 6 ⁇ is a substituent other than hydrogen.
  • R 4 ⁇ or R 5 ⁇ is optionally substituted heteroaryl or heterocycle; and at least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , or R 6 ⁇ is a substituent other than hydrogen.
  • one of the A or B rings has only hydrogen substituents.
  • R 5 ⁇ is optionally substituted thienyl or benzothienyl;
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , or R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , and R 6 ⁇ are independently hydrogen, methoxy, ethoxy, propoxy, benzyloxy, 4-carboxybenzyloxy, 4-ethoxycarbonylbenzyloxy, 4-aminobenzyloxy, fluoro, chloro, bromo, iodo, hydroxy, OCH 2 CO 2 H, SCH 2 CO 2 H, NHCH 2 CO 2 H, CO 2 H, pyrid-2- ylmethoxy, pyrid-3 -ylmethoxy, pyrid-4-yhnethoxy; thien-2-ylmethoxy, thien-3 -ylmethoxy, fur- 2-ylme
  • At least one of R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ or R 6 ⁇ is or R 2 ⁇ and R 3 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ , R 5 ⁇ and R 6 ⁇ , R 2 ⁇ and R 3 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 or R 5 and R 6 ⁇ join to form a carbocycle, aryl, heterocycle or heteroaromatic in which the carbocycle, aryl, heteroaryl or heterocycle is a 5, 6 or 7 membered ring, optionally conjugated to another carbocycle, aryl, heteroaryl or heterocycle.
  • R 3 ⁇ and R 4 ⁇ or R 5 and R 4 ⁇ join to form a 5- membered methylendioxyphenyl group.
  • the compounds of the formula (I) are of the more specific formula (II):
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ are defined above.
  • the optionally substituted carbocycle, aryl, heteroaryl or heterocycle is a 5, 6 or 7 membered ring, optionally substituted or conjugated to another optionally substituted carbocycle, aryl, heteroaryl or heterocycle.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof wherein;
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6ct are independently selected from alkyl, alkoxy, hydroxy, halogen, preferably chloro, heterocycle, heteroaromatic, OC(R 1 ) 2 CO 2 H wherein R 1 is H, or lower alkyl, O-alkylheteroaryl and R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ are independently selected from alkyl, alkoxy, hydroxy, halogen, preferably F or Br, carbocycle, aryl, heterocycle and heteroaryl, preferably thienyl or benzothienyl.
  • the invention provides trans compounds of formula (II) and a pharmaceutically acceptable salts or prodrugs that exhibit a sufficient solubility in water and an in vitro inhibition of fifty percent of VCAM expression at 10 micromolar concentration.
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ is selected from halogen, alkoxy, hydroxy, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC ⁇ COaH; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl; the remaining R / ⁇ groups are selected independently from H; halogen, thio, cyano, nitro, optionally substituted alkyl; cycloalkyl; hydroxy; alkoxy; alkylthio; alkylamino, aminoalkyl, haloalkylthio; haloalkyl; carboxyl derivatives; aryloxy; arylalkoxy; heteroaryloxy; heteroarylalkoxy, amido; acylamino; amino, dialkylamino; trifluoroalk
  • R ⁇ / ⁇ groups can join to form a 5, 6 or 7 membered optionally substituted carbocycle, aryl, heteroaryl or heterocycle, optionally conjugated to another optionally substituted carbocycle, aryl, heteroaryl.
  • the invention provides trans compounds of formula (II) and a pharmaceutically acceptable salts or prodrugs that increase the solubility of the molecule while maintaining or increasing the inhibition of VCAM expression
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ is selected from OCCR ⁇ C ⁇ H, SC(R 1 ) 2 CO 2 H, NHC(R 1 ) 2 CO 2 H or their salts;
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ are selected independently from H; halogen, thio, cyano, nitro, optionally substituted alkyl; cycloalkyl; hydroxy; alkoxy; alkylthio; alkylamino, aminoalkyl, haloalkylthio; haloalkyl; carboxyl derivatives; aryloxy; arylalkoxy; heteroaryloxy; heteroarylalkoxy, amido; acylamino; amino, diaikylamino; trifluoroaikoxy; aikylsulfbnyl, haloalkylsulfonyl; sulfonic acid; sulfonate, sulfate, sulfinic acid, sulfenic acid, sulfamide, sulfonamide; sulfoxide, metal sulfmate, phosphate, phosphonate, metal
  • R / ⁇ groups can join to form a 5, 6 or 7 membered optionally substituted carbocycle, aryl, heteroaryl or heterocycle, optionally conjugated to another optionally substituted carbocycle, aryl, heteroaryl.
  • the invention provides trans compounds of formula (II) and a pharmaceutically acceptable salts or prodrugs that increase the solubility of the molecule while maintaining or increasing the inhibition of VCAM expression
  • R 2 ⁇ is selected from OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl
  • R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R 3 ⁇ , R 4 , R 5 ⁇ and R 6 ⁇ are selected independently from H; halogen, thio, cyano, nitro, optionally substituted alkyl; cycloalkyl; hydroxy; alkoxy; alkylthio; alkylamino, aminoalkyl, haloalkylthio; thio; cyano; halo; haloalkyl; nitro; carboxyl derivatives; aryloxy; arylalkoxy; heteroaryloxy; heteroarylalkoxy, amido; acylamino; amino, diaikylamino; trifluoroaikoxy; aikylsulfbnyl, haloalkylsulfonyl; sulfonic acid; sulfonate, sulfate, sulfinic acid, sulfenic acid, sul
  • R 2 ⁇ and R 3 ⁇ , R ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ , R 5 ⁇ and R 6 ⁇ , R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ or R 5 ⁇ and R ⁇ can join to form a 5, 6 or 7 membered optionally substituted carbocycle, aryl, heteroaryl or heterocycle, optionally conjugated to another optionally substituted carbocycle, aryl, heterocycle or heteroaryl.
  • the invention provides compounds of the formula (II) and a pharmaceutically acceptable salts or prodrugs that are metabolically stable:
  • R 4 ⁇ and R 4 ⁇ are independently selected from cyano; halo; nitro; substituted or unsubstituted alkyl; cycloalkyl; alkoxy; alkylthio; alkylamino; aminoalkyl; haloalkylthio; haloalkyl; carboxyl derivatives; aryloxy; arylalkoxy; heteroaryloxy; heteroarylalkoxy, amido; acylamino; amino, diaikylamino; trifluoroaikoxy; aminocarbonyl; alkenyl; alkynyl; alditol; carbohydrate; aryl; heteroaryl; and heterocycle; or
  • R 3 ⁇ and R 4 ⁇ ; R 4 ⁇ and R 5 ⁇ ; R 3 ⁇ and R 4 ⁇ ; or R 4 ⁇ and R 5 ⁇ ; independently form a 5-7 membered optionally substituted carbocyclic, aryl; heteroaryl or heterocyclic ring;
  • R ⁇ ⁇ groups are selected independently from H; halogen, thio, cyano, nitro, optionally substituted alkyl; cycloalkyl; hydroxy; alkoxy; alkylthio; alkylamino, aminoalkyl, haloalkylthio; haloalkyl; carboxyl derivatives; aryloxy; arylalkoxy; heteroaryloxy; heteroarylalkoxy, amido; acylamino; amino, diaikylamino; trifluoroaikoxy; alkylsulfonyl, haloalkylsulfonyl; sulfonic acid; sulfonate, sulfate, sulfinic acid, sulfenic acid, sulfamide, sulfonamide; sulfoxide, metal sulfmate, phosphate, phosphonate, metal phosphonate, phosphinate aminocarbonyl; alkenyl
  • R 00 ⁇ groups can join to form a 5, 6 or 7 membered optionally substituted carbocycle, aryl, heteroaryl or heterocycle, optionally conjugated to another optionally substituted carbocycle, aryl, heteroaryl, and
  • Ri is H; or lower alkyl; or in a preferred embodiment the invention provides trans compounds of formula (II) and a pharmaceutically acceptable salts or prodrugs that are metabolically stable:
  • R 4 ⁇ and R 4 ⁇ independently from each other are selected from halogen preferably F or heteroaryl preferably thienyl and benzothienyl and, and R 3 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R 3 , R 5 ⁇ and R 6 ⁇ are selected from H, cyano; nitro; halo preferably F; optionally substituted alkyl; cycloalkyl; alkoxy; alkylthio; alkylamino; aminoalkyl; haloalkylthio; haloalkyl; carboxyl derivatives; aryloxy; amido; acylamino; amino, diaikylamino; trifluoroaikoxy; aminocarbonyl; alkenyl; alkynyl; alditol; carbohydrate; aryl; heteroaryl; and heterocycle; or
  • R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ , R 3 ⁇ and R 4 ⁇ , or R ⁇ and R 5 ⁇ independently can join to form a 5-7 membered optionally substituted carbocylic; aryl; heteroaryl; or heterocyclic ring; and
  • R ⁇ ⁇ groups are selected independently from H; halogen, thio, cyano, nitro, optionally substituted alkyl; cycloalkyl; hydroxy; alkoxy; alkylthio; alkylamino, aminoalkyl, haloalkylthio; haloalkyl; carboxyl derivatives; aryloxy; arylalkoxy; heteroaryloxy; heteroarylalkoxy, amido; acylamino; amino, diaikylamino; trifluoroaikoxy; alkylsulfonyl, haloalkylsulfonyl; sulfonic acid; sulfonate, sulfate, sulfinic acid, sulfenic acid, sulfamide, sulfonamide; sulfoxide, metal sulfmate, phosphate, phosphonate, metal phosphonate, phosphinate aminocarbonyl; alkenyl
  • R / ⁇ groups can join to form a 5, 6 or 7 membered optionally substituted carbocycle, aryl, heteroaryl or heterocycle, optionally conjugated to another optionally substituted carbocycle, aryl, heteroaryl, and
  • R 1 is H; or lower alkyl.
  • the invention provides trans compounds of formula (II) and a pharmaceutically acceptable salts or prodrugs: wherein: at least one of the following pairs R 3 ⁇ and R 4 ⁇ , R 4 ⁇ and R 5 ⁇ , R 3 ⁇ and R 4 ⁇ , or R 4 ⁇ and R 5 ⁇ comes together to form a 5, 6 or 7 membered optionally substituted heteroaryl or optionally substituted heterocycle, optionally conjugated to another optionally substituted carbocycle, optionally substituted aryl, or heteroaryl, wherein the heteroatom of the ring is selected from O, S or N; and
  • R ⁇ / ⁇ groups are independently selected from H; halogen, thio, cyano, nitro, optionally substituted alkyl; cycloalkyl; hydroxy; alkoxy; alkylthio; alkylamino, aminoalkyl, haloalkylthio; haloalkyl; carboxyl derivatives; aryloxy; arylalkoxy; heteroaryloxy; heteroarylalkoxy, amido; acylamino; amino, diaikylamino; trifluoroaikoxy; alkylsulfonyl, haloalkylsulfonyl; sulfonic acid; sulfonate, sulfate, sulfinic acid, sulfenic acid, sulfamide, sulfonamide; sulfoxide, metal sulfmate, phosphate, phosphonate, metal phosphonate, phosphinate aminocarbonyl; alkenyl
  • R / ⁇ groups can join to form a 5, 6 or 7 membered optionally substituted carbocycle, aryl, heteroaryl or heterocycle, optionally conjugated to another optionally substituted carbocycle, aryl, heteroaryl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ , R 3 ⁇ , R 4 , R 5 ⁇ and R 6 ⁇ are independently selected from alkyl, alkoxy, halogen, preferably Cl, Br or I, heteroaryl, O-alkylheterocycle, O-akylheteroaryl, carboxyalkyl;
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ are independently selected from alkyl, alkoxy, halogen, preferably F or Br, or heteroaryl, preferably benzothienyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 3 ⁇ and R 6 ⁇ are independently H;
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ are independently selected from H, OH, OR (R is lower alkyl), halogen, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 2 ⁇ , R 4 ⁇ and R 5 ⁇ are independently selected from O-alkyl, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt; and
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ , R 6 ⁇ , R 3 ⁇ and R 6 ⁇ are H;
  • R 3 ⁇ , R 5 ⁇ , R 3 ⁇ and R 6 ⁇ are OMe
  • R 4 ⁇ is OC(R 1 ) 2 CO 2 H, CO 2 H, SC(R 1 ) 2 CO 2 H or NHC(R 1 ) 2 C0 2 H; or its pharmaceutically acceptable salt;
  • R 1 is H or lower alkyl;
  • R 5 ⁇ is a heteroaryl or heterocycle.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof: wherein;
  • R 3 ⁇ and R 6 ⁇ are H;
  • R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 4 ⁇ are OMe
  • R 2 ⁇ is selected from OCCR ⁇ CC l, CO 2 H, SC(R 1 ) 2 CO 2 H or NHCj ⁇ COzH; or its pharmaceutically acceptable salt;
  • R 1 is H or lower alkyl;
  • R 5 ⁇ is a heteroaryl or heterocycle.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ , R 6 ⁇ , R 3 ⁇ and R 6 ⁇ are H;
  • R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 2 ⁇ and R 4 ⁇ are OMe
  • R 5 ⁇ is a heteroaryl or heterocycle.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ , R 6 ⁇ , R 2 ⁇ and R 6 ⁇ are H;
  • R 3 ⁇ , R 4 ⁇ , R 5 ⁇ , R 3 ⁇ and R 4 ⁇ are OMe
  • R 5 ⁇ is a heteroaryl or heterocycle.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 3 ⁇ and R 6 ⁇ are H
  • R 2 ⁇ and R 4 ⁇ are OMe and,
  • R 2 ⁇ R 3 ⁇ R 4 ⁇ R 5 ⁇ md R 6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, H 2 , aminoalkyl, aminodialkyl, SO H, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ -aminoacid, heterocycle, OC(R 1 ) 2 CO 2 H, CO 2 H, S R ⁇ COzH or NHC(R 1 )2CO 2 H; or its pharmaceutically acceptable salt;
  • R 1 is H or lower alkyl; and
  • R 5 ⁇ is a heteroaryl
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 3 ⁇ , R 5 ⁇ and 6 ⁇ are H
  • R 4 ⁇ is OMe and
  • R 2 ⁇ is OC(R 1 ) 2 CO 2 H, CO 2 H, SC(R 1 ) 2 CO 2 H or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 2 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 ,
  • O-alkyl CO 2 H, NH 2 , aminoalkyl, aminodialkyl, SO 3 H, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ -aminoacid, heterocycle, heteroaryl, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt; and
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ and R 6 ⁇ are H and,
  • R 4 ⁇ , R 3 ⁇ , R 4 ⁇ and R 5 ⁇ are OMe and,
  • R 2 ⁇ is OCCR 1 )2C0 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 3 ⁇ , R 5 ⁇ andR 6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, NH 2 , aminoalkyl, aminodialkyl, SO 3 H, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ - aminoacid, heterocycle, heteroaryl, OC(R 1 ) 2 CO 2 H, SC(R 1 ) CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt; and
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ , and R 6 ⁇ are independently H and,
  • R 4 ⁇ , R 3 ⁇ , R 4 ⁇ , R 5 ⁇ and R 6 ⁇ are OMe and,
  • R 3 ⁇ , R 5 ⁇ and R 6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, NH 2 , aminoalkyl, aminodialkyl, SO 3 H, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ - aminoacid, heterocycle, heteroaryl, C(R 1 ) 2 CO 2 H, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC R ⁇ CO ⁇ ; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ and R 6 ⁇ are H and,
  • R 3 ⁇ , R 4 ⁇ , R 3 ⁇ , R 4 ⁇ and R 5 ⁇ are OMe and,
  • R 2 ⁇ , R 5 ⁇ andR 6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, NH 2 , aminoalkyl, aminodialkyl, SO 3 H, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ - aminoacid, heterocycle, heteroaryl, C(R ! ) 2 CO 2 H, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 3 ⁇ , R 4 ⁇ and R 6 ⁇ are H
  • R 4 ⁇ is OMe and
  • R 2 ⁇ is C(R 1 ) 2 CO 2 H, OC(R l )2CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 2 ⁇ _ R e ⁇ are i n( i e p en( i en tiy selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, NH 2 , aminoalkyl, aminodialkyl, sulfonic acid, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ - aminoacid, heterocycle, heteroaryl, C(R 1 ) 2 CO H, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 3 ⁇ , R 5 ⁇ nd R 6 ⁇ are H;
  • R 2 ⁇ andR 4 ⁇ are OMe
  • R 2 ⁇ -R 6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, NH 2 , aminoalkyl, aminodialkyl, sulfonic acid, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ - aminoacid, heterocycle, heteroaryl, C(R 1 ) 2 CO 2 H, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO2H; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ , R 5 ⁇ andR 6 ⁇ are H;
  • R 3 ⁇ and R 4 ⁇ are OMe
  • R 2 ⁇ -R 6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, NH 2 , aminoalkyl, aminodialkyl, sulfonic acid, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ - aminoacid, heterocycle, heteroaryl, C(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ , R 3 ⁇ andR 6 ⁇ are H;
  • R 4 ⁇ is OMe and
  • R 4 ⁇ and R 5 ⁇ together form a five or six membered substituted heterocylic ring and,
  • R 2 ⁇ is OC R- ⁇ COzH, SC ⁇ COzH, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 3 ⁇ , R 5 ⁇ and R 6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, NH 2 , aminoalkyl, aminodialkyl, sulfonic acid, sulfonamine, sulfonaminodi- and mono- alkyl, ⁇ -aminoacid, heterocycle, heteroaryl, C(R 1 ) 2 CO 2 H, OC ⁇ CO ⁇ , SC(R 1 ) 2 CO 2 H, or NHC(R 1 )2CO 2 H; or its pharmaceutically acceptable salt; and
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ , R 3 ⁇ andR 6 ⁇ are H;
  • R 4 ⁇ and R 5 ⁇ together form a five or six membered substituted heterocylic ring
  • R 2 ⁇ andR 4 ⁇ are methoxy
  • R 3 ⁇ , R 5 ⁇ andR 6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, NH 2 , aminoalkyl, aminodialkyl, sulfonic acid, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ - aminoacid, heterocycle, heteroaryl, C(R 1 ) 2 CO 2 H, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt; and
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 2 ⁇ , R 3 ⁇ andR 6 ⁇ are H;
  • R 4 ⁇ and R 5 ⁇ together form a five or six membered substituted heterocylic ring
  • R 3 ⁇ andR 4 ⁇ are methoxy
  • R 2 ⁇ , R 5 ⁇ andR 6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, NH 2 , aminoaikyl, aminodialkyl, SO 3 H, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ - aminoacid, heterocycle, heteroaryl, C(R 1 ) 2 CO 2 H, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt; and
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 3 ⁇ andR 6 ⁇ are H
  • R 2 ⁇ is methoxy and
  • R 4 ⁇ is selected from OC(R 1 ) 2 CO 2 H, SC ⁇ COzH, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 2 ⁇ "6 ⁇ are independently selected from H, OH, SH, halo, alkyl, CF 3 , O-alkyl, CO 2 H, NH 2 , aminoalkyl, aminodialkyl, sulfonic acid, sulfonamine, sulfonaminodi- and mono-alkyl, ⁇ - aminoacid, heterocycle, heteroaryl, C(R x ) 2 C ⁇ 2 ⁇ ., OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and their pharmaceutically acceptable salts or prodrugs thereof:
  • R 3 ⁇ , R 6 ⁇ and R 6 ⁇ are H
  • R 4 ⁇ is OMe
  • R 2 ⁇ is selected from OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl
  • R 5 ⁇ is heteroaryl preferably 2-benzothienyl and, 2-thienyl and,
  • R 2 ⁇ and R 4 ⁇ are independently H, or OMe and,
  • R 3 ⁇ and R 6 ⁇ and R 6 ⁇ are H and,
  • R 2 ⁇ , R 3 ⁇ , R 4 and R 5 ⁇ are independently H, OH, alkoxy, halo, heteroaryl group, or OCHR 1 CO 2 H; or its pharmaceutically acceptable salt; and
  • R 1 is H, or lower alkyl.
  • the invention provides trans compounds of formula (II) and a pharmaceutically acceptable salts or prodrugs:
  • R 4 ⁇ is alkoxy, halo, preferably F, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHCCR ⁇ CO-zH; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl, preferably methyl
  • R 2 ⁇ , R 6 ⁇ , R 3 ⁇ and R 6 ⁇ are H and,
  • R 3 ⁇ , R 5 ⁇ , R 2 ⁇ and R 4 ⁇ are selected from electron donating groups including but not limited to amino, thiol, alkylthio, alkoxy, preferably OMe;
  • R 5 ⁇ is an heteroaryl including furanyl, pyrrolyl, thienyl or pyridinyl, but preferably benzothienyl.
  • the invention provides trans compounds of formula (II) and a pharmaceutically acceptable salts or prodrugs: wherein;
  • R 2 ⁇ is H, alkoxy, hydroxyl, OCCR ⁇ COzH, SC(R 1 ) 2 CO 2 H, or NHC(R 1 ) 2 CO 2 H; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl, preferably Me
  • R 4 ⁇ , R 5 ⁇ and R 3 ⁇ are independently hydroxy or alkoxyl, preferably methoxy;
  • R 2 ⁇ , R 6 ⁇ , R 3 ⁇ and R 6 ⁇ are independently H;
  • R is hydroxy, alkoxy or halogen, preferably F.
  • R 2 ⁇ is H, hydroxy, alkoxy, OC(R 1 ) 2 CO 2 H, SC(R 1 ) 2 CO 2 H, or NHCCR ⁇ CO-zH; or its pharmaceutically acceptable salt;
  • R 1 is H, or lower alkyl, preferably methyl
  • R 4 ⁇ and R 3 ⁇ are independently hydroxyl or alkoxy, preferably methoxy
  • R 2 ⁇ , R 6 ⁇ , R 3 ⁇ and R 6 ⁇ are H;
  • R 5 ⁇ is heteroaryl, preferably 2-tl ienyl or 2-benzo[b]thienyl;
  • R 4 ⁇ and R 5 ⁇ join to form a 5, 6 or 7 membered optionally substituted carbocycle, aryl, heteroaryl or heterocycle, optionally conjugated to another optionally substituted carbocycle, aryl, or heteroaryl.
  • R 3 ⁇ , R 5 ⁇ , R 6 ⁇ , R 2 ⁇ , R 5 ⁇ and R 6 ⁇ are H;
  • R 2 ⁇ , R 3 ⁇ and R 4 ⁇ are independently halo, preferably F, hydroxyl or alkoxy, preferably methoxy;
  • R 4 ⁇ is an heteroaryl preferably 2-thienyl.
  • R 3 ⁇ R 5 ⁇ ⁇ R 6 ⁇ ⁇ R 2 ⁇ ⁇ R 4 ⁇ avQ independently hydroxy or alkoxy, preferably methoxy
  • R 2 ⁇ , R 6 ⁇ , R 3 ⁇ and R 6 ⁇ are H;
  • R 4 ⁇ is OC(R 1 ) 2 heterocycle or its pharmaceutically acceptable salt
  • R 1 is H, or lower alkyl
  • R 5 ⁇ is heteroaryl preferably benzo[b]thienyl.
  • R 3 ⁇ , R 4 ⁇ , R 4 ⁇ , or R 5 ⁇ is selected from a group consisting of the moieties in the following table (1):
  • R ⁇ / groups are selected independently from H; halogen, thio, cyano, nitro, optionally substituted alkyl; cycloalkyl; hydroxy; alkoxy; alkylthio; alkylamino, aminoalkyl, haloalkylthio; haloalkyl; carboxyl derivatives; aryloxy; arylalkoxy; heteroaryloxy; heteroarylalkoxy, amido; acylamino; amino, diaikylamino; trifluoroaikoxy; alkylsulfonyl, haloalkylsulfonyl; sulfonic acid; sulfonate, sulfate, sulfinic acid, sulfenic acid, sulfamide, sulfonamide; sulfoxide, metal sulfmate, phosphate, phosphonate, metal phosphonate, phosphinate aminocarbonyl; alkenyl
  • R ⁇ ⁇ groups can join to form a 5, 6 or 7 membered optionally substituted carbocycle, aryl, heteroaryl or heterocycle, optionally fused to another optionally substituted carbocycle, aryl, heteroaryl, or heterocycle.
  • Y is a phenyl ring conjugated to another heteroaromatic or heterocycle.
  • the compound is selected from the following:
  • compounds of the present invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, diastereomeric, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase).
  • optically active materials examples include at least the following.
  • enzymatic resolutions - a technique whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme
  • enzymatic asymmetric synthesis - a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer
  • chemical asymmetric synthesis - a synthetic technique whereby the desired enantiomer is synthesized from an achiral precursor under conditions that produce asymmetry (i.e., chirality) in the product, which may be achieved using chiral catalysts or chiral auxiliaries;
  • diastereomer separations - a technique whereby a racemic compound is reacted with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers to diastereomers.
  • the resulting diastereomers are then separated by chromatography or crystallization by virtue of their now more distinct structural differences and the chiral auxiliary later removed to obtain the desired enantiomer;
  • kinetic resolutions refers to the achievement of partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions;
  • the stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions;
  • the barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral nature of the membrane which allows only one enantiomer of the racemate to pass through.
  • alkyl refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon, including but not limited to those of Ci to Cio, and preferably C ⁇ -C 4 , including methyl, ethyl, propyl, isopropyl, cyclopropyl, methylcyclopropyl, butyl, isobutyl, t-butyl, sec-butyl, cyclobutyl, and (cyclopropyl)methyl.
  • the alkyl group specifically includes fluorinated alkyls such as CF 3 and other halogenated alkyls such as CH 2 CF 2 , CF 2 CF , the chloro analogs, and the like.
  • the alkyl group can be optionally substituted with one or more moieties selected from the group consisting of aryl, heteroaryl, heterocyclic, carbocycle, alkoxy, heterocycloxy, heterocylalkoxy, aryloxy; arylalkoxy; heteroaryloxy; heteroarylalkoxy, carbohydrate, amino acid, amino acid esters, amino acid amides, alditol, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, alkylamino, diaikylamino, arylamino, nitro, cyano, thiol, imide, sulfonic acid, sulfate, sulfonyl, sulfanyl, sulfinyl, sulfamoyl, carboxylic ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, thioester
  • aryl refers to phenyl, biphenyl, or naphthyl, and preferably phenyl.
  • the aryl group can be optionally substituted with one or more of the moieties selected from the group consisting of alkyl, heteroaryl, heterocyclic, carbocycle, alkoxy, aryloxy, aryloxy; arylalkoxy; heteroaryloxy; heteroarylalkoxy, carbohydrate, amino acid, amino acid esters, amino acid amides, alditol, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, alkylamino, diaikylamino, arylamino, nitro, cyano, thiol, imide, sulfonic acid, sulfate, sulfonyl, sulfanyl, sulfinyl, sulfamo
  • adjacent groups on the aryl ring may combine to form a 5 to 7 membered carbocyclic, aryl, heteroaryl or heterocylic ring.
  • the aryl ring is substituted with an optionally substituted cycloalkyl (such as cyclopentyl or cylcohexyl), or an alkylene dioxy moiety (for example methylenedioxy).
  • heterocyclic refers to a nonaromatic cyclic group that may be partially (contains at least one double bond) or fully saturated and wherein there is at least one heteroatom, such as oxygen, sulfur, nitrogen, or phosphorus in the ring.
  • heteroaryl or heteroaromatic refers to an aromatic that includes at least one sulfur, oxygen, nitrogen or phosphorus in the aromatic ring.
  • heterocylics and heteroaromatics are pyrrolidinyl, tefrahydrofuryl, piperazinyl, piperidinyl, morpholino, thiomorpholino, tetrahydropyranyl, imidazolyl, pyrolinyl, pyrazolinyl, indolinyl, dioxolanyl, or 1,4-dioxanyl.
  • Suitable protecting groups can include trimethylsilyl, dimethylhexylsilyl, t- butyldimethylsilyl, and t-butyldiphenylsilyl, xrityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenelsulfonyl.
  • thienyl refers to a five member cyclic group wherein the ring contains one sulfur atom and two double bonds.
  • the thienyl group can optionally be substituted with one or more moieties selected from the group consisting of those described above for aryl substituents.
  • benzothienyl refers to a five member cyclic group wherein the ring contains one sulfur atom and two double bonds fused to a phenyl ring.
  • the benzothienyl group can optionally be substituted with one or more moieties selected from the group consisting of those described above for aryl substituents.
  • aralkyl refers to an aryl group as defined above linked to the molecule through an alkyl group as defined above.
  • the aryl and alkyl portions can be optionally substituted as described above.
  • heteroaralkyl refers to an heteroaryl group as defined above linked to the molecule through an alkyl group as defined above.
  • heterocyclealkyl refers to a heterocyclic group bound to the molecule through an alkyl group. The heterocyclic group and the alkyl group can be optionally substituted as described above.
  • aryloxy refers to an aryl group bound to the molecule through an oxygen atom.
  • the aryl group can be optionally substituted as set out above for aryl groups.
  • heteroaryloxy refers to a heteroaryl group bound to the molecule tlirough an oxygen atom.
  • the heteroaryl group can be optionally substituted as set out above for aryl groups.
  • aralkoxy refers to an aryl group attached to an alkyl group which is attached to the molecule through an oxygen atom.
  • the aryl and alkyl groups can be optionally substituted as described above.
  • heterocyclearalkoxy refers to a heterocyclic group attached to an aryl group attached to an alkyl-O- group.
  • the heterocyclic, aryl and alkyl groups can be optionally substituted as described above.
  • halo or halogen includes chloro, bromo, iodo and fluoro.
  • alkoxy refers to a moiety of the structure -O-alkyl, wherein alkyl is as defined above.
  • the alkyl group can be optionally substituted as described above.
  • Alkoxy groups can include OCF 3 , OCH 2 CF 3 , OCF 2 CF 3 and the like.
  • alkylthio refers to an alkyl group attached to the molecule through a sulfur atom.
  • the alkyl group can be optionally substituted as described above.
  • acyl refers to a group of the formula C(O)R', wherein R' is an alkyl, aryl, alkaryl or aralkyl group, or substituted alkyl, aryl, aralkyl or alkaryl, wherein these groups are as defined above.
  • alditol refers to a carbohydrate in which the aldehyde or ketone group has been reduced to an alcohol moiety.
  • the alditols of the present mvention can also be optionally substituted or deoxygenated at one or more positions.
  • substituents include hydrogen, halo, haloalkyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, diaikylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, amino acid, amino acid esters and amides, phosphonyl, phosphinyl, phosphoryl, thioester, thioether, oxime, hydrazine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound.
  • substituents include amine and halo, particularly fluorine.
  • the substituent or alditol can be either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.
  • the alditol may have 3, 4, 5, 6 or 7 carbons. Examples of useful alditols are those derived from reduction of monosaccharides, including specifically those derived from the reduction of pyranose and furanose sugars.
  • carbohydrate refers to a compound of carbon, hydrogen and oxygen that contains an aldehyde or ketone group in combination with at least two hydroxyl groups.
  • the carbohydrates of the present invention can also be optionally substituted or deoxygenated at one or more positions. Carbohydrates thus include substituted and unsubstituted monosaccharides, disaccharides, oligosaccharides, and polysaccharides.
  • the saccharide can be an aldose or ketose, and may comprise 3, 4, 5, 6, or 7 carbons.
  • the carbohydrates are monosaccharides.
  • the carbohydrates are pyranose and furanose sugars.
  • Non limiting examples of pyranose and furanose sugars include threose, ribulose, ketose, gentiobiose, aldose, aldotetrose, aldopentose, aldohexose, ketohexose, ketotetrose, ketopentose, erythrose, threose, ribose, deoxyribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, glactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, dextrose, maltose, lactose, sucrose, cellulose, aldose, amylose, palatinose, trehalose, turanose, cellobiose, amylopectin
  • the carbohydrate can be optionally deoxygenated at any corresponding C-position, and/or substituted with one or more moieties such as hydrogen, halo, haloalkyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, diaikylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, amino acid, amino acid esters, amides, phosphonyl, phosphinyl, phosphoryl, thioester, thioether, oxime, hydrazine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound.
  • moieties such
  • substituents include amine and halo, particularly fluorine.
  • the substituent or carbohydrate can be either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.
  • aryl refers to phenyl, biphenyl, or naphthyl, and preferably phenyl.
  • the aryl group can be optionally substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
  • the term "patient” refers to warm-blooded animals or mammals, and in particular humans, who are in need of the therapy described herein.
  • the term host refers to a unicellular or multicellular organism, including cell lines and animals, and preferably a human.
  • pharmaceutically acceptable salts or “complexes” refers to salts or complexes that retain the desired biological activity of the compounds of the present invention and exhibit minimal undesired toxicological effects.
  • Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, ⁇ - ketoglutarate and ⁇ -glycerophosphate.
  • Suitable inorganic salts may also be formed, including, sulfate, nitrate, bicarbonate and carbonate salts.
  • the pharmaceutically acceptable salts may be made with sufficiently basic compounds such as an amine with a suitable acid affording a physiologically acceptable anion.
  • Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
  • Nonlimiting examples of such salts are (a) acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalcturonic acid; (b) base addition salts formed with metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with a cation formed from ammonia, N,N- dibenzylethylenediamine, D-glucosamine, tetraethylammonium, or ethylened
  • quaternary salts known by those skilled in the art, which specifically include the quaternary ammonium salt of the formula -NR + A " , wherein R is as defined above and A is a counterion, including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamoate, mandeloate, benzyloate, and diphenylacetate).
  • R is as defined above and A is a counterion, including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate
  • prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention.
  • Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound.
  • Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound.
  • the compounds of this invention possess anti-inflammatory activity, or are metabolized to a compound that exhibits such activity.
  • any of the compounds described herein can be administered as a prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the compound.
  • a number of prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of the compound will increase the stability of the chalcone.
  • substituent groups that can replace one or more hydrogens on the compound are alkyl, aryl, steroids, carbohydrates, including sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones and N. Bischofberger, Antiviral Research, 27 (1995) 1-17. Any of these can be used in combination with the disclosed compounds to achieve a desired effect.
  • VCAM is upregulated in a wide variety of disease states, including but not limited to arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia- reperfusion injury, post-angioplasty restenosis, clironic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, and conjunctivitis.
  • arthritis asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection
  • multiple sclerosis systemic lupus erythematosis
  • inflammatory bowel diseases autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia- reperfusion injury, post-angioplasty restenosis, clironic
  • Nontlimiting examples of arthritis include rheumatoid (such as soft-tissue rheumatism and non-articular rheumatism, fibromyalgia, fibrositis, muscular rheumatism, myofascil pain, humeral epicondylitis, frozen shoulder, Tietze's syndrome, fascitis, tendinitis, tenosynovitis, bursitis), juvenile chronic, spondyloarthropaties (ankylosing spondylitis), osteoarthritis, hyperuricemia and arthritis associated with acute gout, chronic gout and systemic lupus erythematosus.
  • rheumatoid such as soft-tissue rheumatism and non-articular rheumatism, fibromyalgia, fibrositis, muscular rheumatism, myofascil pain, humeral epicondylitis, frozen shoulder, Tietze's syndrome, fascit
  • VCAM-1 Human endothelial disorders mediated by VCAM-1 include psoriasis, eczematous dermatitis, Kaposi's sarcoma, as well as proliferative disorders of smooth muscle cells.
  • the compounds disclosed herein can be selected to treat anti-inflammatory conditions that are mediated by mononuclear leucocytes.
  • the compounds of the present invention are selected for the prevention or treatment of tissue or organ transplant rejection.
  • Treatment and prevention of organ or tissue transplant rejection includes, but are not limited to treatment of recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, spleen, small bowel, or corneal transplants.
  • the compounds can also be used in the prevention or treatment of graft- versus-host disease, such as sometimes occurs following bone marrow transplantation.
  • the compounds described herein are useful in both the primary and adjunctive medical treatment of cardiovascular disease.
  • the compounds are used in primary treatment of, for example, coronary disease states including atherosclerosis, post-angioplasty restenosis, coronary artery diseases and angina.
  • the compounds can be administered to treat small vessel disease that is not treatable by surgery or angioplasty, or other vessel disease in which surgery is not an option.
  • the compounds can also be used to stabilize patients prior to revascularization therapy.
  • MCP-1 monocyte chemoattractant protein- 1
  • smooth muscle proliferation MCP-1
  • MCP-1 monocyte chemoattractant protein- 1
  • MCP-1 is a chemoattractant protein produced by endothelial cells, smooth muscle cells as well as macrophages. MCP-1 promotes integrin activation on endothelial cells thereby facilitating adhesion of leukocytes to VCAM-1, and MCP-1 is a chemoattractant for monocytes.
  • MCP-1 has been shown to play a role in leukocyte recruitment in a number of chronic inflammatory diseases including atherosclerosis, rheumatoid arthritis, and asthma.
  • MCP-1 expression is upregulated in these diseases and as such inhibition of MCP-1 expression represents a desirable property of anti-inflammatory therapeutics.
  • smooth muscle cell hyperplasia and resulting tissue remodeling and decreased organ function is yet another characteristic of many chronic inflammatory diseases including atherosclerosis, chronic transplant rejection and asthma. Inhibition of the hyperproliferation of smooth muscle cells is another desirable property for therapeutic compounds.
  • Any of the compounds disclosed herein can be administered in combination or alternation with a second biologically active agent to increase its effectiveness against the target disorder.
  • the efficacy of a drug can be prolonged, augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, agent that induces a different biological pathway from that caused by the principle drug.
  • a second, and perhaps third, agent that induces a different biological pathway from that caused by the principle drug.
  • the pharmacokinetics, biodistribution or other parameter of the drug can be altered by such combination or alternation therapy.
  • combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the condition.
  • alternation patterns include 1-6 weeks of administration of an effective amount of one agent followed by 1-6 weeks of administration of an effective amount of a second agent.
  • the alternation schedule can include periods of no treatment.
  • Combination therapy generally includes the simultaneous administration of an effective ratio of dosages of two or more active agents.
  • agents that can be used in combination or alternation with the chalcones of the present invention are described below in regard to asthma and arthritis.
  • the agents set out below or others can alternatively be used to treat a host suffering from any of the other disorders listed in Section IV or that are mediated by VCAM or MCP- 1.
  • Illustrative second biologically active agents for the treatment of cardiovascular disease are also provided below.
  • the compound of the present invention is administered in combination or alternation with heparin, frusemide, ranitidine, an agent that effects respiratory function, such as DNAase, or immunosuppressive agents, IV gamma globulin, troleandomycin, cyclosporin (Neoral), methotrexate, FK-506, gold compounds such as Myochrysine (gold sodium thiomalate), platelet activating factor (PAF) antagonists such as thromboxane inhibitors, leukotriene-D 4 -receptor antagonists such as Accolate (zafirlukast), Ziflo (zileuton), leukotriene Ci or C 2 antagonists and inhibitors of leukotriene synthesis such as zileuton for the treatment of asthma, or an inducible nitric oxide synthase inhibitor.
  • an agent that effects respiratory function such as DNAase, or immunosuppressive agents
  • IV gamma globulin such as Tween, or
  • the active compound is administered in combination or alternation with one or more other prophylactic agent(s).
  • prophylactic agents that can be used in alternation or combination therapy include but are not limited to sodium cromoglycate, Intal (cromolyn sodium, Nasalcrom, Opticrom, Crolom, Ophthalmic Crolom),
  • Tilade nedocromil, nedocromil sodium
  • ketotifen
  • the active compound is administered in combination or alternation with one or more other ⁇ 2 -adrenergic agonist(s) ( ⁇ agonists).
  • ⁇ 2 -adrenergic agonists ⁇ agonists
  • ⁇ agonists include but are not limited to albuterol (salbutamol, Proventil, Ventolin), terbutaline, Maxair (pirbuterol), Serevent (salmeterol), epinephrine, metaproterenol (Alupent, Metaprel), Brethine (Bricanyl, Brethaire, terbutaline sulfate), Tornalate (bitolterol), isoprenaline, ipratropium bromide, bambuterol hydrochloride, bitolterol meslyate, broxaterol, carbuterol hydrochloride, clenbuterol hydrochloride, clorprenaline hydrochloride, efirm
  • the active compound is administered in combination or alternation with one or more other corticosteriod(s).
  • corticosteriods that can be used in alternation or combination therapy include but are not limited to glucocorticoids (GC), Aerobid (Aerobid-M, flunisolide), Azmacort (triamcinolone acetonide), Beclovet (Vanceril, beclomethasone dipropionate), Flo vent (fluticasone), Puhnicort (budesonide), prednisolone, hydrocortisone, adrenaline, Alclometasone Dipropionate, Aldosterone, Amcinonide, Beclomethasone Dipropionate, Bendacort, Betamethasone (Betamethasone Acetate, Betamethasone Benzoate, Betamethasone Dipropionate, Betamethasone Sodium Phosphate, Betamethasone Valerate), Budesonide, Ciclomethasone, Ciprocinonide, Ciclo
  • the active compound is administered in combination or alternation with one or more other antihistimine(s) (Hi receptor antagonists).
  • antihistimines Hi receptor antagonists
  • antihistimines include alkylamines, ethanolamines ethylenediamines, piperazines, piperidines or phenothiazines.
  • antihistimes Chlortrimeton (Teldrin, chlorpheniramine), Atrohist (brompheniramine, Bromarest, Bromfed, Dimetane), Actidil (triprolidine), Dexchlor (Poladex, Polaramine, dexchlo heriiramine), Benadryl (diphen- hydramine), Tavist (clemastine), Dimetabs (dimenhydrinate, Dramamine, Marmine), PBZ (tripelennamine), pyrilamine, Marezine (cyclizine), Zyrtec (cetirizine), hydroxyzine, Antivert (meclizine, Bonine), Allegra (fexofenadine), Hismanal (astemizole), Claritin (loratadine), Seldane (terfenadine), Periactin (cyproheptadine), Nolamine (phenindamine, Nolahist), Phenameth (promethazine, Phen
  • the compound of the present invention is administered in combination or alternation with
  • xanthines and methylxanthines such as Theo-24 (theophylline, Slo-Phylline, Uniphyllin, Slobid, Theo-Dur), Choledyl (oxitriphylline), aminophylline;
  • anticholinergic agents such as belladonna alkaloids, Atrovent (ipratropium bromide), atropine, oxitropium bromide;
  • the compound of the present invention can also be administered in combination or alternation with apazone, amitriptyline, chymopapain, collegenase, cyclobenzaprine, diazepam, fluoxetine, pyridoxine, ademetionine, diacerein, glucosamine, hylan (hyaluronate), misoprostol, paracetamol, superoxide dismutase mimics, TNF ⁇ receptor antagonists, TNF ⁇ antibodies, P38 Kinase inhibitors, tricyclic antidepressents, cJun kinase inhibitors or immunosuppressive agents, FV gamma globulin, froleandomycin, cyclosporin (Neoral), methotrexate, FK-506, gold compounds such as Myochrysine (gold sodium thiomalate), platelet activating factor (PAF) antagonists such as thromboxane inhibitors, leukotriene-D 4
  • apazone
  • the active compound is administered in combination or alternation with one or more other corticosteriod(s).
  • corticosteriods that can be used in alternation or combination therapy include but are not limited to glucocorticoids (GC), Aerobid (Aerobid-M, flunisolide), Azmacort (triamcinolone acetonide), Beclovet (Vanceril, beclomethasone dipropionate), Flovent (fluticasone), Puhnicort (budesonide), prednisolone, hydrocortisone, adrenaline, Alclometasone Dipropionate, Aldosterone, Amcinonide, Beclomethasone Dipropionate, Bendacort, Betamethasone (Betamethasone Acetate, Betamethasone Benzoate, Betamethasone Dipropionate, Betamethasone Sodium Phosphate, Betamethasone Valerate), Budesonide, Ciclomethasone, Ciprocinonide, Ciclo
  • the active compound is administered in combination or alternation with one or more other non-steroidal anti-inflammatory drug(s) (NSAIDS).
  • NSAIDS non-steroidal anti-inflammatory drug(s)
  • NSAIDS that can be used in alternation or combination therapy are carboxylic acids, propionic acids, fenamates, acetic acids, pyrazolones, oxicans, alkanones, gold compounds and others that inhibit prostaglandin synthesis, preferably by selectively inhibiting cylcooxygenase-2 (COX-2).
  • COX-2 inhibitors are Celebrex (celecoxib) and Vioxx (rofacoxib).
  • NSAIDS are aspirin (acetylsalicylic acid), Dolobid (diflunisal), Disalcid (salsalate, salicylsalicylate), Trisilate (choline magnesium trisalicylate), sodium salicylate, Cuprimine (penicillamine), Tolectin (tolmetin), ibuprofen (Motrin, Advil, Nuprin Rufen), Naprosyn (naproxen, Anaprox, naproxen sodium), Nalfon (fenoprofen), Orudis (ketoprofen), Ansaid (flurbiprofen), Daypro (oxaprozin), meclofenamate (meclofanamic acid, Meclomen), mefenamic acid, Indocin (indomethacin), Clinoril (sulindac), tolmetin, Voltaren (diclofenac), Lodine (etodolac), ketorolac, Butazolidin (phenylsalicylic
  • Compounds useful for combining with the compounds of the present invention for the treatment of cardiovascular disease encompass a wide range of therapeutic compounds.
  • Heal bile acid transporter (IBAT) inhibitors are useful in the present invention, and are disclosed in patent application no. PCT/US95/10863, herein incorporated by reference. More LB AT inhibitors are described in PCT/US97/04076, herein incorporated by reference. Still further IBAT inhibitors useful in the present invention are described in U.S. Application Serial No. 08/816,065, herein incorporated by reference. More IBAT inhibitor compounds useful in the present invention are described in WO 98/40375, and WO 00/38725, herein incorporated by reference. Additional IBAT inhibitor compounds useful in the present invention are described in U.S. Application Serial No. 08/816,065, herein incorporated by reference.
  • the second biologically active agent is a statin.
  • Statins lower cholesterol by inhibiting of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, a key enzyme in the cholesterol biosynthetic pathway.
  • HMG CoA 3-hydroxy-3-methylglutaryl coenzyme A
  • the statins decrease liver cholesterol biosynthesis, which increases the production of LDL receptors thereby decreasing plasma total and LDL cholesterol (Grundy, S. M. New Engl. J. Med. 319, 24 (1988); Endo, A. J. Lipid Res. 33, 1569 (1992)).
  • statins may decrease plasma triglyceride levels and may increase HDLc.
  • statins on the market are lovastatin (Merck), simvastatin (Merck), pravastatin (Sankyo and Squibb) and fluvastatin (Sandoz).
  • a fifth statin, atorvastatin (Parke-D avail/Pfizer) is the most recent entrant into the statin market. Any of these statins or thers can be used in combination with the chalcones of the present invention.
  • MTP inhibitor compounds useful in the combinations and methods of the present invention comprise a wide variety of structures and functionalities. Some of the MTP inhibitor compounds of particular interest for use in the present invention are disclosed in WO 00/38725, the disclosure from which is incorporated by reference. Descriptions of these therapeutic compounds can be found in Science, 282, 23 October 1998, pp. 751-754, herein incorporated by reference.
  • Cholesterol absorption antagonist compounds useful in the combinations and methods of the present invention comprise a wide variety of structures and functionalities. Some of the cholesterol absorption antagonist compounds of particular interest for use in the present invention are described in U.S. Patent No. 5,767,115, herein incorporated by reference. Further cholesterol absorption antagonist compounds of particular interest for use in the present invention, and methods for making such cholesterol absorption antagonist compounds are described in U.S. Patent No. 5,631,365, herein incorporated by reference.
  • phytosterols suitable for the combination therapies of the present invention are described by Ling and Jones in "Dietary Phytosterols: A Review of Metabolism, Benefits and Side Effects," Life Sciences, 57 (3), 195-206 (1995). Without limitation, some phytosterols of particular use in the combination of the present invention are Clofibrate, Fenofibrate, Ciprofibrate, Bezafibrate, Gemfibrozil. The structures of the foregoing compounds can be found in WO 00/38725.
  • Phytosterols are also referred to generally by Nes (Physiology and Biochemistry of
  • the phytosterol preferably comprises a stanol.
  • the stanol is campestanol.
  • the stanol is cholestanol.
  • the stanol is clionastanol.
  • the stanol is coprostanol.
  • the stanol is 22,23 -dihydrobrassicastanol. In another embodiment the stanol is epicholestanol. In another preferred embodiment the stanol is fucostanol. In another preferred embodiment the stanol is stigmastanol.
  • the present invention encompasses a therapeutic combination of a compound of the present invention and an HDLc elevating agent.
  • the second HDLc elevating agent can be a CETP inhibitor.
  • Individual CETP inhibitor compounds useful in the present invention are separately described in WO 00/38725, the disclosure of which is herein incorporated by reference.
  • Other individual CETP inhibitor compounds useful in the present invention are separately described in WO 99/14174, EP818448, WO 99/15504, WO 99/14215, WO 98/04528, and WO 00/17166, the disclosures of which are herein incorporated by reference.
  • the second biologically active agent can be a fibric acid derivative.
  • Fibric acid derivatives useful in the combinations and methods of the present invention comprise a wide variety of structures and functionalities which have been reported and published in the art.
  • the present invention encompasses a therapeutic combination of a compound of the present invention and an antihypertensive agent. Hypertension is defined as persistently high blood pressure.
  • the chalcone is administered in combination with an ACE inhibitor, a beta andrenergic blocker, alpha andrenergic blocker, angiotensin II receptor antagonist, vasodilator and diuretic.
  • Any host organism including a pateint, mammal, and specifically a human, suffering from any of the above-described conditions can be treated by the administration of a composition comprising an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier or diluent.
  • composition can be administered in any desired manner, including oral, topical, parenteral, intravenous, intradermal, infra-articular, intra-synovial, intrathecal, intra-arterial, intracardiac, intramuscular, subcutaneous, intraorbital, intracapsular, intraspinal, intrasternal, topical, transdermal patch, via rectal, vaginal or urethral suppository, peritoneal, percutaneous, nasal spray, surgical implant, internal surgical paint, infusion pump, or via catheter.
  • the agent and carrier are administered in a slow release formulation such as an implant, bolus, microparticle, microsphere, nanoparticle or nanosphere.
  • a slow release formulation such as an implant, bolus, microparticle, microsphere, nanoparticle or nanosphere.
  • an effective dose for any of the herein described conditions can be readily determined by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the effective dose, a number of factors are considered including, but not limited to: the species of patient; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; and the use of concomitant medication.
  • Typical systemic dosages for all of the herein described conditions are those ranging from OJ mg/kg to 500 mg/kg of body weight per day as a single daily dose or divided daily doses.
  • Preferred dosages for the described conditions range from 5-1500 mg per day.
  • a more particularly preferred dosage for the desired conditions ranges from 25-750 mg per day.
  • Typical dosages for topical application are those ranging from 0.001 to 100% by weight of the active compound.
  • the compound is administered for a sufficient time period to alleviate the undesired symptoms and the clinical signs associated with the condition being treated.
  • the active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutic amount of compound in vivo in the absence of serious toxic effects.
  • the concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets.
  • the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the compound or its salts can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the compound can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action.
  • the compounds can also be administered in combination with nonsteroidal antiinflammatories such as ibuprofen, indomethacin, fenoprofen, mefenamic acid, flufenamic acid, sulindac.
  • nonsteroidal antiinflammatories such as ibuprofen, indomethacin, fenoprofen, mefenamic acid, flufenamic acid, sulindac.
  • the compound can also be administered with corticosteriods.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • preferred carriers are physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions including liposomes targeted to infected cells with monoclonal antibodies to viral antigens
  • These may be prepared according to methods known to those skilled in the art, for example, as described in U.S.
  • liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the compound is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
  • appropriate lipid(s) such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol
  • Suitable vehicles or carriers for topical application can be prepared by conventional techniques, such as lotions, suspensions, ointments, creams, gels, tinctures, sprays, powders, pastes, slow-release transdermal patches, suppositories for application to rectal, vaginal, nasal or oral mucosa.
  • thickening agents include petrolatum, beeswax, xanthan gum, or polyethylene, humectants such as sorbitol, emollients such as mineral oil, lanolin and its derivatives, or squalene.
  • any of the compounds described herein for combination or alternation therapy can be administered as any derivative that upon administration to the recipient, is capable of providing directly or indirectly, the parent compound, or that exhibits activity itself.
  • Nonlimiting examples are the pharmaceutically acceptable salts (alternatively referred to as "physiologically acceptable salts"), and a compound which has been alkylated or acylated at an appropriate position.
  • physiologically acceptable salts alternatively referred to as "physiologically acceptable salts”
  • the modifications can affect the biological activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the derivative and testing its anti-inflammatory activity according to known methods.
  • a number of the compounds of the general formula (I) are known, whereas many of the compounds of the general formula (I) are novel compounds.
  • the known compounds may be isolated or synthesized in accordance with methods from literature or methods analogous thereto, an non-limiting example is taught by Wade et al, Organic Chemistry Third Edition, 1995.
  • the novel compounds may, likewise, be produced by methods known per se or methods which are analogous to such methods.
  • Compounds of general formula (I) are prepared by reacting an aryl or cyclic substituted ketone with an aryl or cyclic substituted aldehyde.
  • This reaction which is a condensation reaction, is suitably carried out under acid or base catalyzed conditions.
  • the reaction may be suitably carried out in water or protic organic solvents such as lower alcohols (e.g. methanol, ethanol, or tert-butanol), or lower carboxylic acid (e.g. formic acid, glacial acetic acid, or propionic acid), or in aprotic organic solvents such as ethers (e.g. tetrahydrofuran, dioxane, or diethyl ether), liquid amides (e.g.
  • the base may be selected from sodium, lithium, potassium, barium, calcium, magnesium, aluminum, ammomum, or quarternary ammomum hydroxides, lower alkoxides (e.g. methoxides, ethoxides, tert-butoxides), carbonates, borates, oxides, hydrides, or amides of lower secondary amines (e.g. diisopropyl amides or methylphenyl amides).
  • Primary aromatic amines such as aniline, free secondary amines such as dimethyl amine, diethyl amine, piperidine, or pyrrolidine as well as basic ion exchange resins may also be used.
  • Acid catalysts may be selected from hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, sulfonic acids (such as paratoluenesulfonic or methansulfonic acid), lower carboxylic acid (such as formic, acetic, or propionic acid), lower halogenated carboxylic acid (such as trifluoroacetic acid), Lewis acids (such as BF 3s POCl , PC1 5 , FeCl 3 ), or acid ion exchange resins.
  • sulfonic acids such as paratoluenesulfonic or methansulfonic acid
  • lower carboxylic acid such as formic, acetic, or propionic acid
  • lower halogenated carboxylic acid such as trifluoroacetic acid
  • Lewis acids such as BF 3s POCl , PC1 5 , FeCl 3
  • acid ion exchange resins such as BF 3s POCl , PC1 5 , FeCl 3
  • the reaction may be carried out at temperatures in the range of 0-100°C, preferrably at room temperature.
  • the time of reaction may be from 30 minutes to 24 hours.
  • l,3-bis-(substituted-phenyl)-2-propen-l-one compounds of the present invention can be readily prepared by someone skilled in the art of organic synthesis using commonly known methods, many of which are described by D. N. Dnar in The Chemistry of Chalcones and Related Compounds (Wiley-Interscience, New York, 1981), that is incorporated herein by reference.
  • Scheme 1 through Scheme 6 typically a substituted acetophenone is condensed with a substituted benzaldehyde in the presence of a suitable base in a common procedure known as an aldol condensation reaction.
  • a variety of organic and inorganic bases can be used. Sodium hydroxide is a preferred inorganic base.
  • the reaction can be carried out in a variety of different solvents. Either protoic or aprotic solvents may be used. Ethanol is preferred in the presence of an inorganic base. On either or both of the phenyl rings there is a halogen substutution, with iodo and bromo being preferred.
  • a heteroaryl or heterocyclic ring is then introduced to replace the halogen substitution on either one or both of the phenyl rings tlirough a metal-catalyzed cross-coupling carbon- carbon bond forming reaction well known in the art of organic chemistry.
  • a variety of metal- catalyzed cross coupling carbon-carbon bond forming reactions can be used.
  • the palladium- catalyzed Suzuki reaction is preferred, and general methods for this procedure are described by A. Suzuki in Recent Advances in the Cross-Coupling Reactions of Organoboron Derivatives with Organic Electrophiles, 1995-1998 (J. Organomet. Chem. (1999), 576(1-2), 147-168), incorporated herein by reference.
  • this cross-coupling reaction can be done on either phenyl ring after the l,3-bis-(substituted-phenyl)-2-propen-l-one skeleton has been assembled to provide l,3-bis-(substituted-phenyl)-2-propen-l-ones containing one or more heteroaryl or heterocyclic ring.
  • the cross-coupling reaction can be done on the individual acetophenone or benzaldehyde intermediates prior to the aldol condensation, as shown in Schemes 2 and 4. Most of the compounds of this invention are made by either one of these two methods.
  • the aldol condensation reaction can also be carried out in an aquaeous solution using a surfactant.
  • a surfactant can be used. Cetyltrimethylammonium chloride is the preferred surfactant. This method is particularly useful when there are one or more hydroxyl substitutions on either one or both of the phenyl rings.
  • the aldol condensation reaction can also be carried out in an aprotic solvent such as tetrahydrofuran (THF) with an organic base.
  • THF tetrahydrofuran
  • LDA lithium diisopropylamide
  • acetophenones and benzaldehydes are not commercially available. They can be readily prepared by someone skilled in the art of organic synthesis. Since the acetophenones or benzaldehydes may also contain one or more water solubilizing groups (amines, acohols, carboxylates, phosphates, phosphonates, sulfonates, sulfates, etc) that may interfere in the reaction or that may complicate isolation of the desired product, one normally skilled in the art may choose to protect these solubilizing groups prior to the reaction using methods commonly known in the literature such as those described by T. W. Greene and P. G. M. Wuts in Protective Groups in Organic Synthesis (Wiley, New York, 1999) and A.
  • protecting groups include acetates to protect alcohols, esters to protect carboxylic acids, and amides or carbamates to protect amines.
  • Compounds of the present invention include the resulting protected intermediates.
  • One skilled in the art can selectively remove these protecting groups using well established and known procedures to give the desired deprotected heteroaryl or heterocyclic l,3-bis-(substituted-phenyl)-2-propen-l-one products.
  • Some protecting groups such as carboxylic esters may be removed during the aldol condensation reaction.
  • Formation of the resulting carboxylate salts may facilitate isolation of the desired heteroaryl or heterocyclic l,3-bis-(substituted-phenyl)-2- propen-1-one products from the reaction mixture.
  • acidification of the reaction mixture prior to or during workup may facilitate the isolation of the desired free carboxylic, phosphonic, phosphinic or sulfonic acid derivatives.
  • Various salts of the compounds of this invention can be prepared by someone skilled in the art of organic synthesis. Such salts, e.g. amine hydrochlorides, can be directly isolated from the reaction mixture after acidification or formed separately after isolation of the corresponding free amine.
  • HetCyc heterocyclic ring
  • Ex-1A S ⁇ '-Trimethoxyacetophenone (1.47 g, 6.9 mmol) and 3-bromo-4,5- dimethoxybenzaldehyde (1.64 g, 0.67 mmol) were suspended in ethanol (50 mL). Sodium hydroxide solution (50%, 1 mL) was added dropwise. The mixture was stirred at room temperature for 2 h. Water (20 mL) was added.
  • Example Table 1 Substituted l-Phenyl-3-[(Heteroaryl)phenyl]-2-propen-l-ones.
  • Example Table 2a Substituted l-[(Heteroaryl)phenyl]- 3-phenyl -2-propen-l-ones and Substituted 3-[(Heteroaryl)phenyl]-l-phenyl-2-propen-l-ones.
  • Example Table 2b Cyclic Substituted l-[(Heteroaryl)phenyl]- 3-phenyl -2-propen-l-ones and Substituted 3-[(Heteroaryl)phenyl]-l-phenyl-2-propen-l-ones.
  • EX-57A 4'-iodo-2'-methoxyacetophenone (1.08 g, 3.9 mmol) in ethylene glycol dimethyl ether (50 ml) was degassed for 15 minutes. Tetrakis(triphenylphosphine)palladium(0) (0.456 g, 0.39 mmol), thiophene-2-boronic acid (0.75 g, 5.9 mmol), and sodium carbonate solution (2 m, 4 ml, 8 mmol) were added. The mixture was stirred at reflux under nitrogen for 24 hours. Upon cooling to room temperature, it was poured into water and extracted with dichloromethane. The organic phase was dried over sodium sulfate and evaporated. Silica gel chromatography (hexane/ethyl acetate, 3:1) gave 0.88 g (98%) of the desired 2'-methoxy-4'- (thien-2-yl)aceto ⁇ henone.
  • HetCyc heterocyclic ring
  • Ex-59B To a solution of 3',5'-dimethoxy-4'-(tert-butyldimethylsiloxy)acetophenone, from Ex-59A (0.5 g, 1.6 mmol) in tetrahydrofuran (10 mL) chilled with ice/water was added lithium diisopropylamide ( 2 M, 0.8 mL, 1.6 mmol). The mixture was stirred for 20 minutes while chilled.
  • Ex-62A A solution of 2-hydroxy-4-methoxybenzaldehyde (3.03 g, 20 mmol) in 25 mL of dichloromethane was cooled to 0 °C and treated dropwise with a solution of bromine (3.41 g, 21 mmol) in 10 mL of dichloromethane. The reaction mixture was stirred at 0 °C for 1.5 hours. The solvent was removed by rotary evaporation to give a residue. The residue was taken up in EtOAc and washed with 3 portions of water. The organic layer was dried over MgSO .
  • Ex-62B A stream of N 2 was bubbled through a solution of 5-brorno-2-hydroxy-4- methoxybenzaldehyde (1 g, 4.3 mmol) from Ex-62A in 30 mL of ethylene glycol dimethyl ether for 15 min. Tefrakis-triphenylphosphine palladium (0) (0.5 g, 0.4 mmol) was added along with thio ⁇ hene-2-boronic acid (1.2 g, 6.5 mmol) and 10 mL of Na 2 CO 3 (2M aqueous solution). The resulting mixture was stirred under reflux overnight. The solvent was removed by rotary evaporation and the residue was treated with saturated NaHCO 3 and extracted with dichloromethane.
  • Ex-62C A solution of 5-benzo[b]thien-2-yl-2-hydroxy-4-methoxybenzaldehyde (1 g, 3.5 mmol) from Ex-62B and triphenylphosphine (1.0 g, 3.9 mmol) in 20 mL of THF was stirred and treated with ethyl glycolate (0.4 g, 3.9 mmol) and diefhyl azodicarboxylate (0.7 mL, 3.9 mmol), The resulting mixture was stirred under reflux for 2 h. The solvent was removed by rotary evaporation and the residue was recrystallized from hexanes/EtOAc to give 0.34 g of product.
  • Example Table 7 3-[5-(Heteroaryl or Heterocyclic)-2-carboxymethoxy-4-methoxyphenyl]- l-[(3,4,5-trimethoxy)phenyl]-2-propen-l-ones.
  • Example Table 8 3-[5-(Heteroaryl or HeterocycIic)-2,4-dimethoxyphenyl]- l-[(3,4,5-trimethoxy)phenyl]-2-propen-l-ones.
  • Example Table 12 3-[3 or 6-(Heteroaryl)-2-carboxymethoxy-4-methoxy)phenyl]- l-[(3,4,5-trimethoxy)phenyl]-2-propen-l-ones.
  • Example Table 13 3-[3 or 6-(Heteroary ⁇ )-2,4-dimethoxy)phenyl]-l-[(3,4,5- trimethoxy)phenyl]-2-propen-l-ones.
  • Example Table 14 3-[2- or 6-(Heteroaryl)-3,4-dimethoxy)phenyl]-l-[(3,4,5- trimethoxy)phenyl]-2-propen-l-ones.
  • Example Table 15 Substituted l-[2- or 3-(Heteroaryl)-phenyl]-3-[(2-carboxymethoxy)-4- methoxyphenyl]-2-propen-l-ones.
  • Example Table 18 Substituted 3-[3-, 5- or 6-(Heteroary ⁇ )-2-(carboxymethoxy)-4- methoxyphenyl]-l-phenyI-2-propen-l-ones.
  • Example Table 21 Substituted 3-[5-(benzo[b]thien-2-yl)-4-carboxymethoxy-2- methoxyphenyrj-l-phenyl-2-propen-l-ones.
  • Example Table 23 Substituted 3-[4-(heteroaryl or heterocyclic)-2,4-dimethoxyphenyl]-l- [(3,5-dimethoxy)-4-carboxymethoxyphenyl]-2-propen ⁇ l-ones.
  • Example Table 24 3-[4-(Heteroaryl or Heterocyclic)-2-carboxymethoxy-4-methoxyphenyI]- l-[(3,4,5-trimethoxy)phenyl]-2-propen-l-ones.
  • Example Table 25 3-[4-(Heteroaryl or Heterocyclic)-2,4-dimethoxyphenyl]- l-[(3,4,5-trimethoxy)phenyl]-2-propen-l-ones.
  • Example Table 26 3-[4-(Heteroaryl or Heterocyclic) ⁇ 3,5-dimethoxyphenyl]-l-[(3,4,5- trimethoxy)phenyl]-2-propen-l-ones.
  • Example Table 27 Substituted 3-[4-(pyran-2-yl)phenyl]-l-[(3,5-dimethoxy)phenyl]-2- propen-1-ones.
  • Example Table 28 Substituted 3-[4-(pyran-4-yl)phenyl]-l-[(3,5-dimethoxy)phenyl]-2- propen-1-ones.
  • Example Table 29 Substituted 3-[5-(benzo[b]thien-2-yl)-2-(2-carboxy-2-propoxy)-4- methoxyphenyrj-l-phenyl-2-propen-l-ones.
  • Two to four confluent PI 50 plates were trypsinized and the cells transferred to a 50 mL conical centrifuge tube. The cells were pelleted, resuspended and counted using the trypan blue exclusion method.
  • Cells were resuspended at a concentration of 36,000 cells/mL and 1 mL was aliquoted per well.
  • Cells were split into 24 well tissue culture plates. The cells in each well should be approximately 90-95% confluent by the following day. Cells should not be older than passage 8.
  • Captured MCP-1 is subsequently detected with a horse radish peroxidase-conjugated anti- MCP-1 antibody for color development. Results are expressed as IC 5 o values (the amount of compound ( ⁇ M) required to achieve a 50% reduction compared to control (cells stimulated with TNF- ⁇ only)).
  • the compounds were added to the plate (each compound is done in duplicate).
  • One plate was prepared for NCAM expression and one plate was prepared for ICAM expression.
  • T ⁇ F was added to each well 100 units/mL T ⁇ F was usually added to each well. Since each lot of T ⁇ F varies in the number of units, each new lot was titrated to determine the optimum concentration. Therefore this concentration changed. If 100 units/mL was being used, T ⁇ F was dilted to 10 units/ ⁇ L and 10 ⁇ L added to each well.
  • Figure 2 is a bar chart graph of the inhibition of eosinophil recruitment (percent eosinophils in the peritoneal fluid) by 50mg/kg/dose of 3-[5-(benzo[b]thien-2-yl)-2,4- dimethoxyphenyl]-l-(3,4,5-trimethoxyphenyl)-2-propen-l-one.
  • test compound wase administered by subcutaneously injection -24, -2, +2 and +6 hrs around the time of ovalbumin challenge. This is a model of allergic inflammation as eosinophils are the major leukocyte recruited into the peritoneum.
  • Figure 3 is a bar chart graph of the inhibition of paw edema in a mouse model of delayed type hypersensitivity by 50mg/kg/dose of 3-[5-(benzo[b]thien-2-yl)-2,4- dimethoxyphenyl]-l-(3,4,5-trimethoxyphenyl)-2-propen-l-one.
  • the test compound was administered by intraperitoneal injection -24, -2 and +6 hrs around the time of metBSA challenge.
  • NCAM-1 will be obvious to those skilled in the art from the foregoing detailed description of the invention. Such modifications and variations are intended to come with the scope of the appended claims.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2001/019720 2000-06-20 2001-06-20 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders WO2001098291A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL15356501A IL153565A0 (en) 2000-06-20 2001-06-20 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
EP01946583A EP1330448A2 (en) 2000-06-20 2001-06-20 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
CA002413878A CA2413878A1 (en) 2000-06-20 2001-06-20 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
BR0111889-7A BR0111889A (pt) 2000-06-20 2001-06-20 1,3-bis-(fenil-substituìdo)-2-propen-1-onas e seu uso para tratar distúrbios mediados por vcam-1
AU6861001A AU6861001A (en) 2000-06-20 2001-06-20 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
JP2002504247A JP2004501147A (ja) 2000-06-20 2001-06-20 １，３−ビス−（置換フェニル）−２−プロペン−１−オン類およびｖｃａｍ−１媒介障害を治療するためのそれらの使用
MXPA02012660A MXPA02012660A (es) 2000-06-20 2001-06-20 1,3-(fenilo-substituido-bis)-2-propen-1-onas y su uso para el tratamiento de padecimientos transmitidos por el vcam-1.
NZ523443A NZ523443A (en) 2000-06-20 2001-06-20 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
ZA2003/00134A ZA200300134B (en) 2000-06-20 2003-01-06 1,3-bis-(substituted -phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21276900P 2000-06-20 2000-06-20
US60/212,769 2000-06-20
US25593400P 2000-12-15 2000-12-15
US60/255,934 2000-12-15

Publications (2)

Publication Number Publication Date
WO2001098291A2 true WO2001098291A2 (en) 2001-12-27
WO2001098291A3 WO2001098291A3 (en) 2002-05-16

Family

ID=26907449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019720 WO2001098291A2 (en) 2000-06-20 2001-06-20 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders

Country Status (13)

Country Link
US (2) US6608101B1 (pt)
EP (1) EP1330448A2 (pt)
JP (1) JP2004501147A (pt)
KR (1) KR20030031500A (pt)
CN (1) CN1447804A (pt)
AU (1) AU6861001A (pt)
BR (1) BR0111889A (pt)
CA (1) CA2413878A1 (pt)
IL (1) IL153565A0 (pt)
MX (1) MXPA02012660A (pt)
NZ (1) NZ523443A (pt)
WO (1) WO2001098291A2 (pt)
ZA (1) ZA200300134B (pt)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005233A1 (fr) * 2002-07-08 2004-01-15 Genfit Derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
WO2004005243A3 (fr) * 2002-07-08 2004-04-22 Genfit Composition a base de derives de 1,3-diphenylprop-2-en-one substitues
WO2006136423A3 (en) * 2005-06-24 2007-03-01 Dsm Ip Assets Bv Medicament for the treatment of impaired glucose metabolism
WO2007005453A3 (en) * 2005-07-01 2007-06-14 Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
EP1623704A4 (en) * 2003-05-02 2009-04-01 Takara Bio Inc THERAPEUTIC AGENT
EA014729B1 (ru) * 2004-05-29 2011-02-28 7ТиЭм ФАРМА А/С Лиганды crth2 рецептора и их применение
WO2011064350A1 (en) * 2009-11-26 2011-06-03 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2011144579A1 (en) 2010-05-17 2011-11-24 Genfit Improved preparation of chalcone derivatives
US8242171B2 (en) 2003-12-29 2012-08-14 President And Fellows Of Harvard College Method for reducing the weight of a subject or inhibiting weight gain in a subject
CN103360338A (zh) * 2013-07-30 2013-10-23 中国科学院新疆理化技术研究所 一种查尔酮苯并噻唑酰胺类衍生物的制备方法和用途
US8809396B2 (en) 2007-02-16 2014-08-19 Synta Pharmaceuticals Corp. Substituted fused-ring compounds for inflammation and immune-related uses
WO2014162106A1 (fr) 2013-04-05 2014-10-09 Universite Claude Bernard Lyon I Nouveaux derives de chalcone presentant une activite anti-allergique
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9241916B2 (en) 2005-06-14 2016-01-26 President And Fellows Of Harvard College Cognitive performance with sirtuin activators
EP3626242A1 (en) 2013-06-07 2020-03-25 The Scripps Research Institute Itraconazole analogs as inhibitors of fibrosis
CN111004107A (zh) * 2019-01-14 2020-04-14 山东大学 含丙烯酮的取代二氯苯化合物及制备方法与应用
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2020190890A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics Inc. Nicorandil derivatives
WO2022169284A1 (ko) * 2021-02-04 2022-08-11 리퓨어생명과학 주식회사 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물
CN116217461A (zh) * 2023-02-22 2023-06-06 贵州大学 一种含吲哚结构的查耳酮类衍生物及其制备方法与应用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013548A1 (fr) * 2001-08-09 2003-02-20 Sekisui Chemical Co., Ltd. Composition medicale a usage externe destinee au traitement des dermatoses
EP1465854A4 (en) * 2001-12-19 2005-06-08 Atherogenics Inc CHALCONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
AU2004232858B2 (en) 2003-04-23 2009-07-09 Mannkind Corporation Hydraulically actuated pump for long duration medicament administration
US7173129B2 (en) * 2003-06-06 2007-02-06 Athero Genics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
EP2289504A3 (en) 2003-07-01 2012-05-23 President and Fellows of Harvard College SIRT1 modulators for manipulating cell/organism lifespan/stress response
BRPI0506718A (pt) * 2004-01-08 2007-05-02 Genfit compostos, processo de preparação dos mesmos, e, composição farmacêutica ou cosmética
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
JP2008505097A (ja) * 2004-07-01 2008-02-21 アセロジエニクス・インコーポレイテツド 糖尿病性血管疾患を治療するための化合物および方法
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
US20060057216A1 (en) * 2004-09-15 2006-03-16 Salamone Joseph C Low-obscuration image transmitting particulate ocular therapeutic formulations
US7495052B2 (en) * 2004-09-15 2009-02-24 Bausch & Lomb Incorporated Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
AU2007233231B2 (en) 2006-03-30 2011-02-24 Mannkind Corporation Multi-cartridge fluid delivery device
CN1888906B (zh) * 2006-07-17 2010-07-14 长沙安迪生物科技有限公司 盐酸克伦特罗——莱克多巴胺二联检测卡及其检测样品的处理方法
KR100934706B1 (ko) * 2006-12-07 2009-12-31 재단법인서울대학교산학협력재단 Ｔｍ４ｓｆ５의 기능을 저해하는 항암물질의 스크리닝 방법및 칼콘계 화합물을 함유하는 항암조성물
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
ES2429592T3 (es) * 2008-04-22 2013-11-15 Toyama Chemical Co., Ltd. Combinación de un derivado de benzofenona o de una sal del mismo y de un agente inmunosupresor y composición farmacéutica que contiene estos componentes
AU2009256253B2 (en) * 2008-06-04 2013-05-16 Baylor College Of Medicine Stat3 inhibitors
EP2408302A4 (en) * 2009-03-17 2012-08-15 Aciex Therapeutics Inc OPHTALMIC FORMULATIONS OF KTOTICENE AND METHODS OF USE
KR101307494B1 (ko) * 2010-07-07 2013-09-11 주식회사 엘지화학 광반응성 작용기를 갖는 화합물, 광반응성 중합체 및 이를 포함하는 배향막
EP2675893B1 (en) 2011-02-18 2019-01-09 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
WO2014005274A1 (zh) * 2012-07-03 2014-01-09 海南卫康制药(潜山)有限公司 多取代的8-氮杂环【3.2.1】辛烷化合物
CN108658908B (zh) 2017-07-31 2019-05-10 广州必贝特医药技术有限公司 1，3-二取代烯酮类化合物及其应用
AU2019255755B2 (en) 2018-04-19 2024-07-25 Baylor College Of Medicine STAT3 inhibitors
US11026905B2 (en) 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
CN108904481B (zh) * 2018-10-11 2021-06-29 温州医科大学 邻羟基查尔酮类似物在制备抗氧化药物中的应用
CN109705017B (zh) * 2019-01-22 2022-09-20 中美（河南）荷美尔肿瘤研究院 一种查尔酮吲哚衍生物在制备抗肿瘤药物中的应用
CN109651226B (zh) * 2019-01-22 2022-06-07 中美（河南）荷美尔肿瘤研究院 一种查尔酮吲哚衍生物、其制备方法及应用
US11246860B2 (en) * 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
AU2021209679A1 (en) 2020-01-24 2022-06-16 Tvardi Therapeutics, Inc. Therapeutic compounds, formulations, and uses thereof
KR20220162642A (ko) * 2021-06-01 2022-12-08 주식회사 에즈큐리스 신규 불소-치환 플라보노이드 유도체 및 이를 포함하는 알러지성 질환의 예방 또는 치료용 약학적 조성물
CN113413777B (zh) * 2021-07-30 2022-07-12 南京理工大学 Vzif-67/zif-67-聚酰亚胺混合基质膜、制备方法及其应用
WO2023244946A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. Prodrugs of stat3 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787838R (fr) * 1971-08-25 1973-02-22 Delalande Sa Nouveaux derives du cinnamoyl-5 benzofuranne, leur procede de preparation et leur utilisation en therapeutique
FR2175634A1 (en) * 1972-03-16 1973-10-26 Delalande Sa Carboxymethoxybenzofurans derivs - analgesic antiinflammatory hypotensive activity etc
FR2217001B2 (pt) * 1973-02-12 1976-03-12 Delalande Sa
JPS5297950A (en) * 1976-02-13 1977-08-17 Taisho Pharmaceut Co Ltd Chalconeether derivatives
JPS6310720A (ja) * 1986-07-01 1988-01-18 Nippon Kayaku Co Ltd ５−リポキシゲナ−ゼ阻害剤および抗アレルギ−剤
US4904697A (en) 1987-04-09 1990-02-27 Merrell Dow Pharmaceuticals Inc. Controlling the growth of certain tumor tissue with chalcone derivatives
US6159988A (en) * 1992-01-16 2000-12-12 Hoeschst Aktiengesellschaft Arylcycloalkyl derivatives, their production and their use
JPH0692950A (ja) * 1992-09-16 1994-04-05 Kanegafuchi Chem Ind Co Ltd エポキシ化合物の製造方法
JPH06116206A (ja) * 1992-10-02 1994-04-26 Morinaga Milk Ind Co Ltd カルコン誘導体及びその用途
JPH07330814A (ja) * 1994-06-06 1995-12-19 Hitachi Chem Co Ltd 光開始剤、感光性組成物、感光材料及びレリーフパターンの製造法
IT1271301B (it) 1994-12-20 1997-05-27 Indena Spa Calconi naturali e sintetici e loro esteri ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno e formulazioni che li contengono
JP3895404B2 (ja) * 1996-05-17 2007-03-22 興和株式会社 カルコン誘導体及びこれを含有する医薬
DE19648793A1 (de) * 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
ATE304350T1 (de) * 1997-05-14 2005-09-15 Atherogenics Inc Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
US6423740B1 (en) 1997-06-19 2002-07-23 Indena S.P.A. Chalcones having antiproliferative activity
AU7908098A (en) * 1997-06-26 1999-01-19 Statens Serum Institut Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943661B2 (en) 2002-07-08 2011-05-17 Genfit Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
EA012699B1 (ru) * 2002-07-08 2009-12-30 Женфит Композиция на основе замещенных производных 1,3-дифенилпроп-2-ен-1-она и ее применение
JP2005532386A (ja) * 2002-07-08 2005-10-27 ジェンフィ 置換１，３−ジフェニルプロパ−２−エン−１−オン誘導体に基づく組成物、その調製及び使用
US8058308B2 (en) 2002-07-08 2011-11-15 Genfit Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
US8461212B2 (en) 2002-07-08 2013-06-11 Genfit Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
EA011090B1 (ru) * 2002-07-08 2008-12-30 Женфит Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
WO2004005243A3 (fr) * 2002-07-08 2004-04-22 Genfit Composition a base de derives de 1,3-diphenylprop-2-en-one substitues
US7632870B2 (en) 2002-07-08 2009-12-15 Genfit Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
AU2003264698B2 (en) * 2002-07-08 2009-09-17 Genfit Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
US7566737B2 (en) 2002-07-08 2009-07-28 Genfit Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients
US8106097B2 (en) 2002-07-08 2012-01-31 Genfit Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
WO2004005233A1 (fr) * 2002-07-08 2004-01-15 Genfit Derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
EP1623704A4 (en) * 2003-05-02 2009-04-01 Takara Bio Inc THERAPEUTIC AGENT
US8846724B2 (en) 2003-12-29 2014-09-30 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US9597347B2 (en) 2003-12-29 2017-03-21 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8242171B2 (en) 2003-12-29 2012-08-14 President And Fellows Of Harvard College Method for reducing the weight of a subject or inhibiting weight gain in a subject
EA014729B1 (ru) * 2004-05-29 2011-02-28 7ТиЭм ФАРМА А/С Лиганды crth2 рецептора и их применение
US9241916B2 (en) 2005-06-14 2016-01-26 President And Fellows Of Harvard College Cognitive performance with sirtuin activators
WO2006136423A3 (en) * 2005-06-24 2007-03-01 Dsm Ip Assets Bv Medicament for the treatment of impaired glucose metabolism
EP2361618A3 (en) * 2005-07-01 2011-12-28 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2007005453A3 (en) * 2005-07-01 2007-06-14 Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8809396B2 (en) 2007-02-16 2014-08-19 Synta Pharmaceuticals Corp. Substituted fused-ring compounds for inflammation and immune-related uses
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US8772342B2 (en) 2009-11-26 2014-07-08 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9782373B2 (en) 2009-11-26 2017-10-10 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10350181B2 (en) 2009-11-26 2019-07-16 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10022343B2 (en) 2009-11-26 2018-07-17 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US8895619B2 (en) 2009-11-26 2014-11-25 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
EA020849B1 (ru) * 2009-11-26 2015-02-27 Женфит Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
EP2641596A1 (en) * 2009-11-26 2013-09-25 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2011064350A1 (en) * 2009-11-26 2011-06-03 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9585853B2 (en) 2009-11-26 2017-03-07 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2011144579A1 (en) 2010-05-17 2011-11-24 Genfit Improved preparation of chalcone derivatives
US9896415B2 (en) 2013-04-05 2018-02-20 Universite Claude Bernard Lyon I Chalcone derivatives having an anti-allergic activity
FR3004180A1 (fr) * 2013-04-05 2014-10-10 Univ Claude Bernard Lyon Nouveaux derives de chalcone presentant une activite anti-allergique
WO2014162106A1 (fr) 2013-04-05 2014-10-09 Universite Claude Bernard Lyon I Nouveaux derives de chalcone presentant une activite anti-allergique
EP3626242A1 (en) 2013-06-07 2020-03-25 The Scripps Research Institute Itraconazole analogs as inhibitors of fibrosis
CN103360338B (zh) * 2013-07-30 2015-04-01 中国科学院新疆理化技术研究所 一种查尔酮苯并噻唑酰胺类衍生物的制备方法和用途
CN103360338A (zh) * 2013-07-30 2013-10-23 中国科学院新疆理化技术研究所 一种查尔酮苯并噻唑酰胺类衍生物的制备方法和用途
CN111004107A (zh) * 2019-01-14 2020-04-14 山东大学 含丙烯酮的取代二氯苯化合物及制备方法与应用
WO2020190890A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics Inc. Nicorandil derivatives
WO2022169284A1 (ko) * 2021-02-04 2022-08-11 리퓨어생명과학 주식회사 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물
CN116217461A (zh) * 2023-02-22 2023-06-06 贵州大学 一种含吲哚结构的查耳酮类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
US20060258735A1 (en) 2006-11-16
AU6861001A (en) 2002-01-02
ZA200300134B (en) 2005-12-28
US6608101B1 (en) 2003-08-19
CA2413878A1 (en) 2001-12-27
JP2004501147A (ja) 2004-01-15
MXPA02012660A (es) 2004-05-14
CN1447804A (zh) 2003-10-08
NZ523443A (en) 2004-11-26
EP1330448A2 (en) 2003-07-30
KR20030031500A (ko) 2003-04-21
BR0111889A (pt) 2003-06-24
WO2001098291A3 (en) 2002-05-16
IL153565A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
US6608101B1 (en) 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
US7078431B2 (en) 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
US7202247B2 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
US7094801B2 (en) Chalcone derivatives and their use to treat diseases
US8193249B2 (en) Triptolide analogs for the treatment of autoimmune and inflammatory disorders
WO2004007423A1 (en) Novel salt forms of poorly soluble probucol esters and ethers
AU2001296542A1 (en) Triptolide analogs for the treatment of autoimmune and inflammatory disorders
JP2004525082A5 (pt)
US7271274B2 (en) Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
US20070093453A1 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases
US7253189B2 (en) Cannabinoid receptor ligands
AU2001268610B2 (en) 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
US20060063828A1 (en) 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
ZA200503708B (en) 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
US20040204394A1 (en) Triptolide analogues
JPS625982A (ja) チアゾリジン誘導体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2413878

Country of ref document: CA

Ref document number: 2001268610

Country of ref document: AU

Ref document number: PA/a/2002/012660

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2002 504247

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 153565

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020027017448

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2003/00008/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 523443

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003/00134

Country of ref document: ZA

Ref document number: 200300134

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001946583

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2003101330

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 018143903

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027017448

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001946583

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 523443

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523443

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001268610

Country of ref document: AU